Entry ID,Ligand,Value,Symbol,Type,Unit,PDB ID,Title,Structure Title,Stucture Keywords,Gene Name,EC Number,Annotation Identifier,Entity ID,Entry Id (Polymer Entity Identifiers),Target Protein,Accession Code(s),Database Name,Ligand Formula,Ligand MW,Ligand ID,Ligand Name,Ligand SMILES,Entity ID
7QRI,,,,,,7QRI,Structural characterization of human tryptophan hydroxylase 2 reveals that L-Phe is superior to L-Trp as the regulatory domain ligand.,Regulatory domain dimer of tryptophan hydroxylase 2 in complex with L-Phe,OXIDOREDUCTASE,"TPH2, NTPH",1.14.16.4,"GO:0005829, GO:0043005, GO:0005506, GO:0004510, GO:0009072, GO:0071285, GO:0007623, GO:0014823, GO:0051592, GO:0043627, GO:0051384, GO:0031667, GO:0042427, IPR045865, IPR002912, IPR001273, IPR018301, IPR036951, IPR036329, IPR019774, IPR005963, IPR041904, IPR019773, Q8IWU9",1,7QRI,wlidetype,Q8IWU9,UniProt,C9 H11 N O2,165.189,PHE,PHENYLALANINE,c1ccc(cc1)CC(C(=O)O)N,2
7QTT,,,,,,7QTT,Structural basis of catalytic activation in human splicing.,"Structural organization of a late activated human spliceosome (Baqr, core region)",SPLICING,"SF3B5, SF3B10",,"GO:0005654, GO:0005634, GO:0071011, GO:0000124, GO:0005681, GO:0005689, GO:0005686, GO:0071005, GO:0005684, GO:0003723, GO:1990935, GO:0043966, GO:0035521, GO:0035522, GO:0000398, GO:0045893, GO:0006282, GO:0043484, GO:1903241, IPR009846, IPR017089, Q9BWJ5",2,7QTT,wlidetype,Q9BWJ5,UniProt,C6 H18 O24 P6,660.035,IHP,INOSITOL HEXAKISPHOSPHATE,C1(C(C(C(C(C1OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O,39
7QTT,,,,,,7QTT,Structural basis of catalytic activation in human splicing.,"Structural organization of a late activated human spliceosome (Baqr, core region)",SPLICING,"SF3B1, SAP155",,"GO:0110016, GO:0071013, GO:0016607, GO:0005730, GO:0005654, GO:0005634, GO:0005681, GO:0034693, GO:0005689, GO:0005686, GO:0071005, GO:0071004, GO:0005684, GO:0003729, GO:0003723, GO:1990935, GO:0006338, GO:0000398, GO:0035066, GO:0045943, GO:0045944, GO:0045945, GO:0008380, GO:0000375, GO:0000245, GO:1903241, IPR011989, IPR016024, IPR015016, IPR038737, O75533",3,7QTT,wlidetype,O75533,UniProt,C10 H16 N5 O14 P3,523.18,GTP,GUANOSINE-5'-TRIPHOSPHATE,c1nc2c(n1C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N=C(NC2=O)N,40
7R2M,,,,,,7R2M,SYNJ2BP PDZ domain in complex with a synthetic Vangl2 peptide.,SYNJ2BP complex with a synthetic Vangl2 peptide (9mer).,MEMBRANE PROTEIN,"SYNJ2BP, OMP25",,"GO:0005604, GO:0005576, GO:0016020, GO:0005509, GO:0005544, GO:0008092, GO:0004859, IPR001464, IPR018502, IPR018252, IPR037104, IPR002389, GO:0016323, GO:0030054, GO:0005739, GO:0031594, GO:0043005, GO:0098839, GO:0098609, GO:0007268, GO:0045197, GO:0016525, GO:0010596, GO:0001937, GO:0070373, GO:1903671, GO:0006605, GO:0043113, GO:0097120, GO:0030100, GO:0008593, GO:0007266, IPR001478, IPR036034, P57105",1,7R2M,wlidetype,P57105,UniProt,C16 H34 O8,354.436,PE4,2-{2-[2-(2-{2-[2-(2-ETHOXY-ETHOXY)-ETHOXY]-ETHOXY}-ETHOXY)-ETHOXY]-ETHOXY}-ETHANOL,CCOCCOCCOCCOCCOCCOCCOCCO,5
7RIG,,,,,,7RIG,Allosteric role of the citrate synthase homology domain of ATP citrate lyase.,Structure of ACLY-D1026A-substrates,TRANSFERASE,ACLY,2.3.3.8,"GO:0035578, GO:0005829, GO:0070062, GO:0005576, GO:1904813, GO:0016020, GO:0005654, GO:0005524, GO:0003878, GO:0046872, GO:0006085, GO:0006695, GO:0006101, GO:0015936, GO:0006633, GO:0008610, GO:0006107, IPR014608, IPR017440, IPR032263, IPR016143, IPR002020, IPR036969, IPR033847, IPR003781, IPR005811, IPR036291, IPR017866, IPR016102, P53396",1,7RIG,mutant,P53396,UniProt,C27 H42 N7 O22 P3 S,941.642,Q5B,(3S)-citryl-Coenzyme A,CC(C)(COP(=O)(O)OP(=O)(O)OCC1C(C(C(O1)n2cnc3c2ncnc3N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)CC(CC(=O)O)(C(=O)O)O)O,3
7RKZ,,,,,,7RKZ,Allosteric role of the citrate synthase homology domain of ATP citrate lyase.,Structure of ACLY D1026A-substrates-asym-int,TRANSFERASE,ACLY,2.3.3.8,"GO:0035578, GO:0005829, GO:0070062, GO:0005576, GO:1904813, GO:0016020, GO:0005654, GO:0005524, GO:0003878, GO:0046872, GO:0006085, GO:0006695, GO:0006101, GO:0015936, GO:0006633, GO:0008610, GO:0006107, IPR014608, IPR017440, IPR032263, IPR016143, IPR002020, IPR036969, IPR033847, IPR003781, IPR005811, IPR036291, IPR017866, IPR016102, P53396",1,7RKZ,mutant,P53396,UniProt,C27 H42 N7 O22 P3 S,941.642,Q5B,(3S)-citryl-Coenzyme A,CC(C)(COP(=O)(O)OP(=O)(O)OCC1C(C(C(O1)n2cnc3c2ncnc3N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)CC(CC(=O)O)(C(=O)O)O)O,3
7RMP,,,,,,7RMP,Allosteric role of the citrate synthase homology domain of ATP citrate lyase.,Structure of ACLY D1026A - substrates-asym,TRANSFERASE,ACLY,2.3.3.8,"GO:0035578, GO:0005829, GO:0070062, GO:0005576, GO:1904813, GO:0016020, GO:0005654, GO:0005524, GO:0003878, GO:0046872, GO:0006085, GO:0006695, GO:0006101, GO:0015936, GO:0006633, GO:0008610, GO:0006107, IPR014608, IPR017440, IPR032263, IPR016143, IPR002020, IPR036969, IPR033847, IPR003781, IPR005811, IPR036291, IPR017866, IPR016102, P53396",1,7RMP,mutant,P53396,UniProt,C27 H42 N7 O22 P3 S,941.642,Q5B,(3S)-citryl-Coenzyme A,CC(C)(COP(=O)(O)OP(=O)(O)OCC1C(C(C(O1)n2cnc3c2ncnc3N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)CC(CC(=O)O)(C(=O)O)O)O,3
7TRS,,,,,,7TRS,Structural and dynamic mechanisms of allostery at the M4 muscarinic acetylcholine receptor,Human M4 muscarinic acetylcholine receptor complex with Gi1 and the endogenous agonist acetylcholine,SIGNALING PROTEIN/IMMUNE SYSTEM,GNB1,,"GO:0005737, GO:0005829, GO:0070062, GO:1903561, GO:0005834, GO:0005765, GO:0016020, GO:0097381, GO:0005886, GO:0045202, GO:0003924, GO:0051020, GO:0044877, GO:0030159, GO:0007191, GO:0008283, GO:0071870, GO:0071380, GO:0007213, GO:0007186, GO:0007200, GO:0007265, GO:0060041, GO:0050909, GO:0007165, IPR020472, IPR001632, IPR016346, IPR015943, IPR001680, IPR019775, IPR036322, P62873",1,7TRS,mutant,P62873,UniProt,C7 H16 N O2,146.207,ACH,ACETYLCHOLINE,CC(=O)OCC[N+](C)(C)C,6
7VPX,,,,,,7VPX,Mechanism for Branch Site Recognition and Proofreading During Prespliceosome Assembly,The cryo-EM structure of the human pre-A complex,SPLICING,"SF1, ZFM1, ZNF162",,"GO:0016604, GO:0005654, GO:0005634, GO:0005840, GO:0005681, GO:0089701, GO:0042802, GO:0003729, GO:0045131, GO:0003723, GO:0003714, GO:0008270, GO:0033327, GO:0030238, GO:0000389, GO:0000398, GO:0048662, GO:0030575, GO:0048024, GO:0050810, GO:0000245, IPR045071, IPR031150, IPR004087, IPR004088, IPR036612, IPR032570, IPR001878, Q15637",2,7VPX,wlidetype,Q15637,UniProt,C28 H45 N O8,523.659,SJT,spliceostatin A (form II),CC1CC(C(OC1CC=C(C)C=CC2C(C(CC(O2)(C)OC)(C)O)O)C)NC(=O)C=CC(C)OC(=O)C,30
7W1M,,,,,,7W1M,Cryo-EM structure of human cohesin-CTCF complex,Cryo-EM structure of human cohesin-CTCF-DNA complex,DNA BINDING PROTEIN/DNA,"RAD21, HR21, KIAA0078, NXP1, SCC1",,"GO:0000785, GO:0005694, GO:0000775, GO:0008278, GO:0005829, GO:0016020, GO:0030496, GO:0016363, GO:0005654, GO:0005634, GO:0000922, GO:0003682, GO:0003677, GO:0006915, GO:0051301, GO:0006310, GO:0006302, GO:0034089, GO:0010972, GO:0045841, GO:0045876, GO:0071168, GO:0007131, GO:0006357, GO:1990414, GO:0007062, IPR039781, IPR006909, IPR006910, IPR023093, IPR036390, O60216",3,7W1M,mutant,O60216,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,9
7XJF,,,,,,7XJF,Blockade of dual immune checkpoint inhibitory signals with a CD47/PD-L1 bispecific antibody for cancer treatment.,Crystal structure of 6MW3211 Fab in complex with CD47,IMMUNE SYSTEM,,,,1,7XJF,mutant,,,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,7
7XUJ,,,,,,7XUJ,human SLC26A3 in complex with UK5099,Human SLC26A3 in complex with UK5099,TRANSPORT PROTEIN,"SLC26A3, DRA",,"GO:0016324, GO:0031526, GO:0016020, GO:0005886, GO:0097225, GO:0015106, GO:0015108, GO:0140900, GO:0019531, GO:0008271, GO:0005452, GO:0015116, GO:0071320, GO:0051454, GO:0060081, GO:0006820, GO:0006811, GO:0048240, IPR018045, IPR011547, IPR001902, IPR002645, IPR036513, P40879, Transmembrane.Alpha-helical polytopic.APC (Amino acid-Polyamine-organoCation) superfamily.Sulfate permease, Generic PDBTM",1,7XUJ,wlidetype,P40879,UniProt,C18 H12 N2 O2,288.3,I2R,(E)-2-cyano-3-(1-phenylindol-3-yl)prop-2-enoic acid,c1ccc(cc1)n2cc(c3c2cccc3)C=C(C#N)C(=O)O,2
7XUL,,,,,,7XUL,Structure of human SLC26A3 in complex with Tenidap,Human SLC26A3 in complex with Tenidap,PROTEIN TRANSPORT,"SLC26A3, DRA",,"GO:0016324, GO:0031526, GO:0016020, GO:0005886, GO:0097225, GO:0015106, GO:0015108, GO:0140900, GO:0019531, GO:0008271, GO:0005452, GO:0015116, GO:0071320, GO:0051454, GO:0060081, GO:0006820, GO:0006811, GO:0048240, IPR018045, IPR011547, IPR001902, IPR002645, IPR036513, P40879, Transmembrane.Alpha-helical polytopic.APC (Amino acid-Polyamine-organoCation) superfamily.Sulfate permease, Generic PDBTM",1,7XUL,wlidetype,P40879,UniProt,C14 H9 Cl N2 O3 S,320.751,I2U,5-chloranyl-2-oxidanyl-3-thiophen-2-ylcarbonyl-indole-1-carboxamide,c1cc(sc1)C(=O)c2c3cc(ccc3n(c2O)C(=O)N)Cl,2
7XY6,,,,,,7XY6,Cryo-EM structure of the human adenosine A 2B receptor-G s signaling complex.,Adenosine receptor bound to an agonist in complex with G protein obtained by cryo-EM,MEMBRANE PROTEIN,cybC,,"GO:0042597, GO:0009055, GO:0020037, GO:0005506, IPR009155, IPR010980, GO:0098978, GO:0005886, GO:0098793, GO:0098685, GO:0001609, GO:0004930, GO:0007190, GO:0007189, GO:0031668, GO:0019934, GO:0007186, GO:0043303, GO:0010753, GO:0032722, GO:0002882, GO:0031284, GO:0032755, GO:0043306, GO:0010575, GO:0099171, GO:0060087, GO:0042311, IPR001435, IPR001634, IPR000276, IPR017452, P29275, Transmembrane.Alpha-helical polytopic.Rhodopsin-like receptors and pumps.G-protein coupled receptors, family A, Generic PDBTM",4,7XY6,mutant,P0ABE7,UniProt,C19 H17 N5 O2 S,379.436,I5D,"2-[6-azanyl-3,5-dicyano-4-[4-(cyclopropylmethoxy)phenyl]pyridin-2-yl]sulfanylethanamide",c1cc(ccc1c2c(c(nc(c2C#N)SCC(=O)N)N)C#N)OCC3CC3,5
7Y48,,,,,,7Y48,Cryo-EM structures of mitochondrial ABC transporter ABCB10 in apo and biliverdin-bound form,Cryo-EM Structure of biliverdin-bound mitochondrial ABC transporter ABCB10 from Biortus,MEMBRANE PROTEIN,ABCB10,,"GO:0005743, GO:0005739, GO:0140359, GO:0005524, GO:0016887, GO:0042803, GO:0048821, GO:0006783, GO:0006839, GO:0034514, GO:0045648, GO:0070455, GO:0046985, IPR003593, IPR011527, IPR036640, IPR003439, IPR017871, IPR030260, IPR027417, IPR039421, Q9NRK6, TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.ATP Binding Cassette (ABC) Transporters.ABCB10 Mitochondrial ABC transporter with bound biliverdin, Transmembrane.Alpha-helical polytopic.ABC transporters.Lipid exporter family, Generic PDBTM",1,7Y48,mutant,Q9NRK6,UniProt,C27 H46 O,386.654,CLR,CHOLESTEROL,CC(C)CCCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C,2
7Y48,,,,,,7Y48,Cryo-EM structures of mitochondrial ABC transporter ABCB10 in apo and biliverdin-bound form,Cryo-EM Structure of biliverdin-bound mitochondrial ABC transporter ABCB10 from Biortus,MEMBRANE PROTEIN,ABCB10,,"GO:0005743, GO:0005739, GO:0140359, GO:0005524, GO:0016887, GO:0042803, GO:0048821, GO:0006783, GO:0006839, GO:0034514, GO:0045648, GO:0070455, GO:0046985, IPR003593, IPR011527, IPR036640, IPR003439, IPR017871, IPR030260, IPR027417, IPR039421, Q9NRK6, TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.ATP Binding Cassette (ABC) Transporters.ABCB10 Mitochondrial ABC transporter with bound biliverdin, Transmembrane.Alpha-helical polytopic.ABC transporters.Lipid exporter family, Generic PDBTM",1,7Y48,mutant,Q9NRK6,UniProt,C33 H34 N4 O6,582.646,IE5,3-[5-[(3-ethenyl-4-methyl-5-oxidanylidene-pyrrol-2-ylidene)methyl]-2-[(~{Z})-[5-[(~{Z})-(4-ethenyl-3-methyl-5-oxidanylidene-pyrrol-2-ylidene)methyl]-3-(3-hydroxy-3-oxopropyl)-4-methyl-pyrrol-2-ylidene]methyl]-4-methyl-1~{H}-pyrrol-3-yl]propanoic acid,Cc1c(c([nH]c1C=C2C(=C(C(=O)N2)C)C=C)C=C3C(=C(C(=N3)C=C4C(=C(C(=O)N4)C=C)C)C)CCC(=O)O)CCC(=O)O,3
7YIR,,,,,,7YIR,Structural Insights Uncover the Specific Phosphoinositide Recognition by the PH1 Domain of Arap3.,Crystal structure of N-terminal PH domain of ARAP3 protein from human,CYTOSOLIC PROTEIN,"ARAP3, CENTD3",,"GO:0005737, GO:0005856, GO:0030027, GO:0005886, GO:0001726, GO:0005096, GO:0046872, GO:0005547, GO:0043325, GO:0007010, GO:0035021, GO:0035024, GO:0043547, GO:0008360, GO:0007165, GO:0016192, IPR037278, IPR001164, IPR038508, IPR011993, IPR001849, IPR000159, IPR008936, IPR037858, IPR000198, IPR001660, IPR013761, IPR029071, Q8WWN8",1,7YIR,wlidetype,Q8WWN8,UniProt,C4 H10 O3,106.12,PEG,DI(HYDROXYETHYL)ETHER,C(COCCO)O,2
7YIS,,,,,,7YIS,Structural Insights Uncover the Specific Phosphoinositide Recognition by the PH1 Domain of Arap3.,"Crystal structure of N-terminal PH domain of ARAP3 protein in complex with inositol 1,3,4,5-tetrakisphosphate",CYTOSOLIC PROTEIN,"ARAP3, CENTD3",,"GO:0005737, GO:0005856, GO:0030027, GO:0005886, GO:0001726, GO:0005096, GO:0046872, GO:0005547, GO:0043325, GO:0007010, GO:0035021, GO:0035024, GO:0043547, GO:0008360, GO:0007165, GO:0016192, IPR037278, IPR001164, IPR038508, IPR011993, IPR001849, IPR000159, IPR008936, IPR037858, IPR000198, IPR001660, IPR013761, IPR029071, Q8WWN8",1,7YIS,wlidetype,Q8WWN8,UniProt,C17 H36 O22 P4,716.35,4PT,"(2R)-3-{[(S)-{[(2S,3R,5S,6S)-2,6-DIHYDROXY-3,4,5-TRIS(PHOSPHONOOXY)CYCLOHEXYL]OXY}(HYDROXY)PHOSPHORYL]OXY}-2-(1-HYDROXY
BUTOXY)PROPYL BUTYRATE",CCCC(O)OC(COC(=O)CCC)COP(=O)(O)OC1C(C(C(C(C1O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)O,2
7YNI,,,,,,7YNI,Structures of human SGLT with substrate bound,Structure of human SGLT1-MAP17 complex bound with substrate 4D4FDG in the occluded conformation,PROTEIN TRANSPORT,"SLC5A1, NAGT, SGLT1",,"GO:0016324, GO:0031526, GO:0005769, GO:0070062, GO:0043229, GO:0097708, GO:0048471, GO:0005886, GO:0015151, GO:0055056, GO:0015150, GO:0005354, GO:0015371, GO:0005355, GO:0005412, GO:0005367, GO:0015146, GO:0005372, GO:0000017, GO:0015756, GO:0015757, GO:0098708, GO:1904659, GO:0001951, GO:0106001, GO:0015798, GO:0015750, GO:0035623, GO:0010035, GO:0098719, GO:0006814, GO:0035377, GO:0150104, IPR038377, IPR001734, IPR018212, P13866, Transmembrane.Alpha-helical polytopic.APC (Amino acid-Polyamine-organoCation) superfamily.Solute:sodium symporter, Generic PDBTM",1,7YNI,wlidetype,P13866,UniProt,C6 H11 F O5,182.147,KQC,"(2R,3R,4R,5S,6R)-5-fluoranyl-6-(hydroxymethyl)oxane-2,3,4-triol",C(C1C(C(C(C(O1)O)O)O)F)O,3
7ZRB,,,,,,7ZRB,Crystal structure of Beta-catenin Armadillo repeats domain in complex with the inhibitor RS6452,Crystal structure of Beta-catenin Armadillo repeats domain in complex with the inhibitor RS6452,CELL ADHESION,CTNNB1,,"GO:0005912, GO:0005886, GO:0045296, GO:0007155, IPR011989, IPR016024, IPR000225, IPR013284",1,7ZRB,wlidetype,A0A2R8Y804,UniProt,C17 H13 Br N2 O2 S,389.266,JKI,4-bromanyl-~{N}-(3-pyridin-2-ylphenyl)benzenesulfonamide,c1ccnc(c1)c2cccc(c2)NS(=O)(=O)c3ccc(cc3)Br,2
7ZT6,,,,,,7ZT6,Structural and functional basis of inositol hexakisphosphate stimulation of NHEJ through its interaction with Ku70-Ku80,Cryo-EM structure of Ku 70/80 bound to inositol hexakisphosphate,DNA BINDING PROTEIN,"XRCC6, G22P1","3.6.4, 4.2.99","GO:0000781, GO:0005829, GO:0070418, GO:0005576, GO:1904813, GO:0043564, GO:0016020, GO:0070419, GO:0000783, GO:0005730, GO:0005654, GO:0005634, GO:0032991, GO:0032993, GO:0034774, GO:0005667, GO:0051575, GO:0005524, GO:0008094, GO:0030332, GO:0003684, GO:0003677, GO:0003678, GO:0003690, GO:0016787, GO:0044877, GO:0003723, GO:0097110, GO:0042162, GO:0000976, GO:0002218, GO:0071480, GO:0071481, GO:0006266, GO:0097680, GO:0006303, GO:0045087, GO:0045892, GO:0045621, GO:0045860, GO:0045944, GO:0045893, GO:0000725, GO:0048660, GO:0000723, IPR006165, IPR006164, IPR027388, IPR005160, IPR005161, IPR003034, IPR036361, IPR016194, IPR036465, P12956",1,7ZT6,wlidetype,P12956,UniProt,C6 H18 O24 P6,660.035,IHP,INOSITOL HEXAKISPHOSPHATE,C1(C(C(C(C(C1OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O,3
7ZVT,,,,,,7ZVT,Structural and functional analysis of the interaction between PAXX and the core NHEJ machinery,CryoEM structure of Ku heterodimer bound to DNA,DNA BINDING PROTEIN,,,,1,7ZVT,wlidetype,,,C6 H18 O24 P6,660.035,IHP,INOSITOL HEXAKISPHOSPHATE,C1(C(C(C(C(C1OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O,5
7ZXN,,,,,,7ZXN,Structures of connexin 32 channels suggest a link between hemichannel gating and disease-associated mutations,cryo-EM structure of Connexin 32 gap junction channel,MEMBRANE PROTEIN,"GJB1, CX32",,"GO:0005922, GO:0005789, GO:0016328, GO:0005243, GO:0042802, GO:0007267, GO:1905867, GO:0016264, GO:0007399, GO:0015868, IPR000500, IPR002267, IPR019570, IPR017990, IPR013092, IPR038359, P08034, Transmembrane.Alpha-helical polytopic.Tetraspan junctional complexes.Connexin, Generic PDBTM",1,7ZXN,wlidetype,P08034,UniProt,C27 H46 O,386.654,CLR,CHOLESTEROL,CC(C)CCCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C,2
8A99,,,,,,8A99,Immunoglobulin germline gene polymorphisms influence the function of SARS-CoV-2 neutralizing antibodies.,SARS Cov2 Spike in 1-up conformation complex with Fab47,VIRAL PROTEIN,S,,"GO:0044173, GO:0020002, GO:0016020, GO:0019031, GO:0055036, GO:0046789, GO:0042802, GO:0075509, GO:0039654, GO:0019064, GO:0061025, GO:0046598, GO:0019065, GO:0046813, GO:0039587, GO:0039502, GO:0046718, GO:0019058, IPR032500, IPR042578, IPR043607, IPR043473, IPR043002, IPR044341, IPR018548, IPR044366, IPR036326, IPR002552, IPR044873, IPR044874, P0DTC2",1,8A99,wlidetype,P0DTC2,UniProt,C8 H15 N O5,205.208,RTV,"2-(acetylamino)-1,5-anhydro-2-deoxy-D-mannitol",CC(=O)NC1COC(C(C1O)O)CO,6
8CH6,,,,,,8CH6,Structural basis of catalytic activation in human splicing.,Structure of a late-stage activated spliceosome (BAqr) arrested with a dominant-negative Aquarius mutant (state B complex).,SPLICING,"SNRPF, PBSCF",,"GO:0071013, GO:0005829, GO:0034709, GO:0005654, GO:0005634, GO:0034715, GO:0030532, GO:0034719, GO:0005681, GO:0005685, GO:0005689, GO:0005686, GO:0071007, GO:0071005, GO:0005687, GO:0046540, GO:0005682, GO:0005683, GO:0003723, GO:0036261, GO:0000398, GO:0008380, GO:0000387, GO:1903241, IPR016487, IPR001163, IPR010920, IPR034100, P62306",2,8CH6,wlidetype,P62306,UniProt,C6 H18 O24 P6,660.035,IHP,INOSITOL HEXAKISPHOSPHATE,C1(C(C(C(C(C1OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O)OP(=O)(O)O,51
8CSJ,,,,,,8CSJ,Cryo-EM structure of NTD-directed non-neutralizing antibody 4-33 in complex with prefusion SARS-CoV-2 spike glycoprotein,Cryo-EM structure of NTD-directed non-neutralizing antibody 4-33 in complex with prefusion SARS-CoV-2 spike glycoprotein,VIRAL PROTEIN/IMMUNE SYSTEM,"S, 2",,"GO:0044173, GO:0020002, GO:0016020, GO:0019031, GO:0055036, GO:0046789, GO:0042802, GO:0075509, GO:0039654, GO:0019064, GO:0061025, GO:0046598, GO:0019065, GO:0046813, GO:0039587, GO:0039502, GO:0046718, GO:0019058, IPR032500, IPR042578, IPR043607, IPR043473, IPR043002, IPR044341, IPR018548, IPR044366, IPR036326, IPR002552, IPR044873, IPR044874, P0DTC2",1,8CSJ,wlidetype,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,6
8CZZ,,,,,,8CZZ,"Cryo-EM structure of T/F100 SOSIP.664 HIV-1 Env trimer with LMHS mutations in complex with Temsavir, 8ANC195, and 10-1074","Cryo-EM structure of T/F100 SOSIP.664 HIV-1 Env trimer with LMHS mutations in complex with Temsavir, 8ANC195, and 10-1074",VIRAL PROTEIN/INHIBITOR,env,,"GO:0044175, GO:0020002, GO:0005886, GO:0019031, GO:0055036, GO:0005198, GO:0075512, GO:0039654, GO:0019064, GO:0019049, GO:1903905, GO:1903908, GO:1903911, GO:0019082, GO:0019062, IPR036377, IPR037527, IPR000328, IPR000777",1,8CZZ,mutant,A0A6C0ZY47,UniProt,C24 H23 N7 O4,473.484,83J,"1-[4-(benzenecarbonyl)piperazin-1-yl]-2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]ethane-1,2-dione",Cc1ncn(n1)c2c3c(c(c[nH]3)C(=O)C(=O)N4CCN(CC4)C(=O)c5ccccc5)c(cn2)OC,14
8D0Q,,,,,,8D0Q,"Structural basis for Lewis antigen synthesis by the alpha 1,3-fucosyltransferase FUT9.",Human FUT9 bound to GDP-CF3-Fucose and H-Type 2,TRANSFERASE,FUT9,2.4.1.152,"GO:0005794, GO:0000139, GO:0005802, GO:0032588, GO:0017083, GO:0046920, GO:0008417, GO:0005975, GO:0036065, GO:0006688, GO:0042355, GO:0036071, GO:0030182, GO:0009312, GO:0000271, GO:0010976, GO:0006486, GO:0006487, GO:0006493, GO:1903037, GO:1903236, IPR031481, IPR001503, IPR038577, Q9Y231",1,8D0Q,mutant,Q9Y231,UniProt,C16 H22 F3 N5 O15 P2,643.313,6CK,"[(2R,3S,4R,5R)-5-(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]methyl (2R,3S,4R,5S,6R)-3,4,5-trihydroxy-6-(trifluoromethyl)tetrahydro-2H-pyran-2-yl dihydrogen diphosphate (non-preferred name)",c1nc2c(n1C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OC4C(C(C(C(O4)C(F)(F)F)O)O)O)O)O)N=C(NC2=O)N,5
8D0Q,,,,,,8D0Q,"Structural basis for Lewis antigen synthesis by the alpha 1,3-fucosyltransferase FUT9.",Human FUT9 bound to GDP-CF3-Fucose and H-Type 2,TRANSFERASE,FUT9,2.4.1.152,"GO:0005794, GO:0000139, GO:0005802, GO:0032588, GO:0017083, GO:0046920, GO:0008417, GO:0005975, GO:0036065, GO:0006688, GO:0042355, GO:0036071, GO:0030182, GO:0009312, GO:0000271, GO:0010976, GO:0006486, GO:0006487, GO:0006493, GO:1903037, GO:1903236, IPR031481, IPR001503, IPR038577, Q9Y231",1,8D0Q,mutant,Q9Y231,UniProt,C10 H15 N5 O11 P2,443.201,GDP,GUANOSINE-5'-DIPHOSPHATE,c1nc2c(n1C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N=C(NC2=O)N,6
8D0R,,,,,,8D0R,"Structural basis for Lewis antigen synthesis by the alpha 1,3-fucosyltransferase FUT9.",Human FUT9 bound to GDP and H-Type 2,TRANSFERASE,FUT9,2.4.1.152,"GO:0005794, GO:0000139, GO:0005802, GO:0032588, GO:0017083, GO:0046920, GO:0008417, GO:0005975, GO:0036065, GO:0006688, GO:0042355, GO:0036071, GO:0030182, GO:0009312, GO:0000271, GO:0010976, GO:0006486, GO:0006487, GO:0006493, GO:1903037, GO:1903236, IPR031481, IPR001503, IPR038577, Q9Y231",1,8D0R,mutant,Q9Y231,UniProt,C10 H15 N5 O11 P2,443.201,GDP,GUANOSINE-5'-DIPHOSPHATE,c1nc2c(n1C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N=C(NC2=O)N,4
8D0S,,,,,,8D0S,"Structural basis for Lewis antigen synthesis by the alpha 1,3-fucosyltransferase FUT9.",Human FUT9 bound to GDP and LNnT,TRANSFERASE,FUT9,2.4.1.152,"GO:0005794, GO:0000139, GO:0005802, GO:0032588, GO:0017083, GO:0046920, GO:0008417, GO:0005975, GO:0036065, GO:0006688, GO:0042355, GO:0036071, GO:0030182, GO:0009312, GO:0000271, GO:0010976, GO:0006486, GO:0006487, GO:0006493, GO:1903037, GO:1903236, IPR031481, IPR001503, IPR038577, Q9Y231",1,8D0S,mutant,Q9Y231,UniProt,C10 H15 N5 O11 P2,443.201,GDP,GUANOSINE-5'-DIPHOSPHATE,c1nc2c(n1C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N=C(NC2=O)N,4
8D0U,,,,,,8D0U,"Structural basis for Lewis antigen synthesis by the alpha 1,3-fucosyltransferase FUT9.",Human FUT9 bound to GDP,TRANSFERASE,FUT9,2.4.1.152,"GO:0005794, GO:0000139, GO:0005802, GO:0032588, GO:0017083, GO:0046920, GO:0008417, GO:0005975, GO:0036065, GO:0006688, GO:0042355, GO:0036071, GO:0030182, GO:0009312, GO:0000271, GO:0010976, GO:0006486, GO:0006487, GO:0006493, GO:1903037, GO:1903236, IPR031481, IPR001503, IPR038577, Q9Y231",1,8D0U,mutant,Q9Y231,UniProt,C10 H15 N5 O11 P2,443.201,GDP,GUANOSINE-5'-DIPHOSPHATE,c1nc2c(n1C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N=C(NC2=O)N,3
8D33,,,,,,8D33,Pol gamma coordinates DNA synthesis and proofreading to ensure mitochondrial genome integrity.,Human mitochondrial DNA polymerase gamma ternary complex with GC basepair,TRANSFERASE/DNA,"POLG2, MTPOLB",,"GO:0005737, GO:0005760, GO:0005759, GO:0042645, GO:0005739, GO:0070182, GO:0030337, GO:0003887, GO:0003690, GO:0042802, GO:0006281, GO:0006261, GO:0001701, GO:0006264, GO:0070584, GO:1900264, GO:0022904, IPR045864, IPR004154, IPR036621, IPR027031, IPR027030, IPR042064, Q9UHN1",2,8D33,wlidetype,Q9UHN1,UniProt,C9 H16 N3 O13 P3,467.157,DCP,2'-DEOXYCYTIDINE-5'-TRIPHOSPHATE,C1C(C(OC1N2C=CC(=NC2=O)N)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O,6
8D37,,,,,,8D37,Pol gamma coordinates DNA synthesis and proofreading to ensure mitochondrial genome integrity.,Human mitochondrial DNA polymerase gamma ternary complex with GT basepair in replication conformer,TRANSFERASE/DNA,"POLG2, MTPOLB",,"GO:0005737, GO:0005760, GO:0005759, GO:0042645, GO:0005739, GO:0070182, GO:0030337, GO:0003887, GO:0003690, GO:0042802, GO:0006281, GO:0006261, GO:0001701, GO:0006264, GO:0070584, GO:1900264, GO:0022904, IPR045864, IPR004154, IPR036621, IPR027031, IPR027030, IPR042064, Q9UHN1",2,8D37,wlidetype,Q9UHN1,UniProt,C9 H16 N3 O13 P3,467.157,DCP,2'-DEOXYCYTIDINE-5'-TRIPHOSPHATE,C1C(C(OC1N2C=CC(=NC2=O)N)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O,6
8D3R,,,,,,8D3R,Pol gamma coordinates DNA synthesis and proofreading to ensure mitochondrial genome integrity.,Human mitochondrial DNA polymerase gamma ternary complex with GT basepair in intermediate conformer,TRANSFERASE/DNA,"POLG, MDP1, POLG1, POLGA",2.7.7.7,"GO:0005760, GO:0005759, GO:0042645, GO:0005739, GO:0032991, GO:0008408, GO:0003682, GO:0003677, GO:0003887, GO:0002020, GO:0006287, GO:0006259, GO:0006261, GO:0006264, IPR019760, IPR002297, IPR001098, IPR043502, IPR041336, IPR012337, P54098",1,8D3R,wlidetype,P54098,UniProt,C9 H16 N3 O13 P3,467.157,DCP,2'-DEOXYCYTIDINE-5'-TRIPHOSPHATE,C1C(C(OC1N2C=CC(=NC2=O)N)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O,5
8D42,,,,,,8D42,Pol gamma coordinates DNA synthesis and proofreading to ensure mitochondrial genome integrity.,Human mitochondrial DNA polymerase gamma ternary complex with GT basepair in editing conformer (composite),TRANSFERASE/DNA,"POLG2, MTPOLB",2.7.7.7,"GO:0005737, GO:0005760, GO:0005759, GO:0042645, GO:0005739, GO:0070182, GO:0030337, GO:0003887, GO:0003690, GO:0042802, GO:0006281, GO:0006261, GO:0001701, GO:0006264, GO:0070584, GO:1900264, GO:0022904, IPR045864, IPR004154, IPR036621, IPR027031, IPR027030, IPR042064, Q9UHN1",2,8D42,wlidetype,Q9UHN1,UniProt,C9 H16 N3 O13 P3,467.157,DCP,2'-DEOXYCYTIDINE-5'-TRIPHOSPHATE,C1C(C(OC1N2C=CC(=NC2=O)N)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O,6
8DNN,,,,,,8DNN,Crystal structure of neutralizing antibody 80 in complex with SARS-CoV-2 receptor binding domain,Crystal structure of neutralizing antibody 80 in complex with SARS-CoV-2 receptor binding domain,IMMUNE SYSTEM/VIRAL PROTEIN,"S, 2",,"GO:0044173, GO:0020002, GO:0016020, GO:0019031, GO:0055036, GO:0046789, GO:0042802, GO:0075509, GO:0039654, GO:0019064, GO:0061025, GO:0046598, GO:0019065, GO:0046813, GO:0039587, GO:0039502, GO:0046718, GO:0019058, IPR032500, IPR042578, IPR043607, IPR043473, IPR043002, IPR044341, IPR018548, IPR044366, IPR036326, IPR002552, IPR044873, IPR044874, P0DTC2",1,8DNN,wlidetype,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,4
8DO0,,,,,,8DO0,A common mechanism of Sec61 translocon inhibition by small molecules.,Cryo-EM structure of the human Sec61 complex inhibited by mycolactone,PROTEIN TRANSPORT/INHIBITOR,SEC61G,,"GO:0005829, GO:0016020, GO:0071261, GO:0008320, GO:0043022, GO:0031204, GO:0045047, IPR023391, IPR008158, IPR001901, P60059, Transmembrane.Alpha-helical polytopic.General secretory pathway (Sec).Protein translocase, Generic PDBTM",1,8DO0,mutant,P60059,UniProt,C44 H70 O9,743.021,Q6B,"[(6~{S},7~{S},9~{Z},12~{R})-12-[(~{Z},2~{S},6~{R},7~{R},9~{R})-4,6-dimethyl-7,9-bis(oxidanyl)dec-4-en-2-yl]-7,9-dimethyl-2-oxidanylidene-1-oxacyclododec-9-en-6-yl] (2~{E},4~{E},6~{E},8~{E},10~{E},12~{S},13~{S},15~{S})-4,6,10-trimethyl-12,13,15-tris(oxidanyl)hexadeca-2,4,6,8,10-pentaenoate",CC1CC(=CCC(OC(=O)CCCC1OC(=O)C=CC(=CC(=CC=CC(=CC(C(CC(C)O)O)O)C)C)C)C(C)CC(=CC(C)C(CC(C)O)O)C)C,4
8DO1,,,,,,8DO1,A common mechanism of Sec61 translocon inhibition by small molecules.,Cryo-EM structure of the human Sec61 complex inhibited by ipomoeassin F,PROTEIN TRANSPORT/INHIBITOR,SEC61B,,"GO:0005829, GO:0005783, GO:0005789, GO:0044322, GO:0031205, GO:0016020, GO:0005784, GO:0048408, GO:0043022, GO:0003723, GO:0031204, GO:0030970, GO:0006616, GO:0030433, IPR030671, IPR016482, P60468, Transmembrane.Alpha-helical polytopic.General secretory pathway (Sec).Protein translocase, Generic PDBTM",3,8DO1,mutant,P60468,UniProt,C44 H62 O15,830.954,SXF,"[(1~{S},3~{R},4~{S},5~{R},6~{R},8~{R},10~{S},23~{R},24~{R},25~{R},26~{R})-5-acetyloxy-6-methyl-4,26-bis(oxidanyl)-17,20-bis(oxidanylidene)-10-pentyl-24-[(~{E})-3-phenylprop-2-enoyl]oxy-2,7,9,21,27-pentaoxatricyclo[21.3.1.0^{3,8}]heptacosan-25-yl] (~{E})-2-methylbut-2-enoate",CCCCCC1CCCCCCC(=O)CCC(=O)OCC2C(C(C(C(O2)OC3C(C(C(OC3O1)C)OC(=O)C)O)O)OC(=O)C(=CC)C)OC(=O)C=Cc4ccccc4,4
8DO2,,,,,,8DO2,A common mechanism of Sec61 translocon inhibition by small molecules.,Cryo-EM structure of the human Sec61 complex inhibited by cyclotriazadisulfonamide (CADA),PROTEIN TRANSPORT/INHIBITOR,SEC61G,,"GO:0005829, GO:0016020, GO:0071261, GO:0008320, GO:0043022, GO:0031204, GO:0045047, IPR023391, IPR008158, IPR001901, P60059, Transmembrane.Alpha-helical polytopic.General secretory pathway (Sec).Protein translocase, Generic PDBTM",1,8DO2,mutant,P60059,UniProt,C31 H39 N3 O4 S2,581.789,SXU,"9-benzyl-1,5-bis(4-methylbenzene-1-sulfonyl)-3-methylidene-1,5,9-triazacyclododecane",Cc1ccc(cc1)S(=O)(=O)N2CCCN(CCCN(CC(=C)C2)S(=O)(=O)c3ccc(cc3)C)Cc4ccccc4,4
8DO3,,,,,,8DO3,A common mechanism of Sec61 translocon inhibition by small molecules.,Cryo-EM structure of the human Sec61 complex inhibited by eeyarestatin I,PROTEIN TRANSPORT/INHIBITOR,SEC61G,,"GO:0005829, GO:0016020, GO:0071261, GO:0008320, GO:0043022, GO:0031204, GO:0045047, IPR023391, IPR008158, IPR001901, P60059, Transmembrane.Alpha-helical polytopic.General secretory pathway (Sec).Protein translocase, Generic PDBTM",1,8DO3,mutant,P60059,UniProt,C27 H26 Cl2 N7 O7,631.444,SWR,"N'-(4-chlorophenyl)-N-[(4R)-3-(4-chlorophenyl)-5,5-dimethyl-1-(2-{(2E)-2-[(2E)-3-(5-nitrofuran-2-yl)prop-2-en-1-ylidene]hydrazinyl}-2-oxoethyl)-2-oxoimidazolidin-4-yl]-N-hydroxyurea",CC1(C(N(C(=O)N1CC(=O)NN=CC=Cc2ccc(o2)[N+](=O)[OH-])c3ccc(cc3)Cl)N(C(=O)Nc4ccc(cc4)Cl)O)C,4
8DZQ,,,,,,8DZQ,Ligand and G-protein selectivity in the kappa-opioid receptor.,momSalB bound Kappa Opioid Receptor in complex with GoA,MEMBRANE PROTEIN,GNB1,,"GO:0005737, GO:0005829, GO:0070062, GO:1903561, GO:0005834, GO:0005765, GO:0016020, GO:0097381, GO:0005886, GO:0045202, GO:0003924, GO:0051020, GO:0044877, GO:0030159, GO:0007191, GO:0008283, GO:0071870, GO:0071380, GO:0007213, GO:0007186, GO:0007200, GO:0007265, GO:0060041, GO:0050909, GO:0007165, IPR020472, IPR001632, IPR016346, IPR015943, IPR001680, IPR019775, IPR036322, P62873",1,8DZQ,mutant,P62873,UniProt,C23 H30 O8,434.48,U99,"methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-2-(furan-3-yl)-9-(methoxymethoxy)-6a,10b-dimethyl-4,10-dioxododecahydro-2H-naphtho[2,1-c]pyran-7-carboxylate",CC12CCC3C(=O)OC(CC3(C1C(=O)C(CC2C(=O)OC)OCOC)C)c4ccoc4,6
8DZR,,,,,,8DZR,Ligand and G-protein selectivity in the kappa-opioid receptor.,"GR89,696 bound Kappa Opioid Receptor in complex with gustducin",MEMBRANE PROTEIN,,,,2,8DZR,mutant,,,C19 H25 Cl2 N3 O3,414.326,U9I,"methyl (3R)-4-[(3,4-dichlorophenyl)acetyl]-3-[(pyrrolidin-1-yl)methyl]piperazine-1-carboxylate",COC(=O)N1CCN(C(C1)CN2CCCC2)C(=O)Cc3ccc(c(c3)Cl)Cl,6
8EA5,,,,,,8EA5,Identification of small-molecule protein-protein interaction inhibitors for NKG2D.,NKG2D complexed with inhibitor 1a,IMMUNOSUPPRESSANT/INHIBITOR,"KLRK1, D12S2489E, NKG2D",,"GO:0009986, GO:0009897, GO:0005886, GO:0030246, GO:0042802, GO:0042288, GO:0032394, GO:0038023, GO:0002250, GO:0030154, GO:0071222, GO:0050830, GO:0030101, GO:0042267, GO:0034260, GO:2000502, GO:0006809, GO:0032729, GO:0045954, GO:0045429, GO:0007165, GO:0002223, GO:0031295, IPR001304, IPR016186, IPR016187, IPR042169, IPR033992, P26718",1,8EA5,mutant,P26718,UniProt,C23 H25 Cl2 N3 O2,446.37,VN8,"(3S,5aS,8aR)-3-benzyl-6-[(3,5-dichlorophenyl)methyl]-1,4-dimethyloctahydropyrrolo[3,2-e][1,4]diazepine-2,5-dione",CN1C2CCN(C2C(=O)N(C(C1=O)Cc3ccccc3)C)Cc4cc(cc(c4)Cl)Cl,2
8EA6,,,,,,8EA6,Identification of small-molecule protein-protein interaction inhibitors for NKG2D.,NKG2D complexed with inhibitor 3e,IMMUNOSUPPRESSANT/INHIBITOR,"KLRK1, D12S2489E, NKG2D",,"GO:0009986, GO:0009897, GO:0005886, GO:0030246, GO:0042802, GO:0042288, GO:0032394, GO:0038023, GO:0002250, GO:0030154, GO:0071222, GO:0050830, GO:0030101, GO:0042267, GO:0034260, GO:2000502, GO:0006809, GO:0032729, GO:0045954, GO:0045429, GO:0007165, GO:0002223, GO:0031295, IPR001304, IPR016186, IPR016187, IPR042169, IPR033992, P26718",1,8EA6,mutant,P26718,UniProt,C25 H20 F6 N2 O2,494.429,VMB,"N-{(1S)-2-(dimethylamino)-2-oxo-1-[3-(trifluoromethyl)phenyl]ethyl}-4'-(trifluoromethyl)[1,1'-biphenyl]-2-carboxamide",CN(C)C(=O)C(c1cccc(c1)C(F)(F)F)NC(=O)c2ccccc2c3ccc(cc3)C(F)(F)F,2
8EA6,,,,,,8EA6,Identification of small-molecule protein-protein interaction inhibitors for NKG2D.,NKG2D complexed with inhibitor 3e,IMMUNOSUPPRESSANT/INHIBITOR,"KLRK1, D12S2489E, NKG2D",,"GO:0009986, GO:0009897, GO:0005886, GO:0030246, GO:0042802, GO:0042288, GO:0032394, GO:0038023, GO:0002250, GO:0030154, GO:0071222, GO:0050830, GO:0030101, GO:0042267, GO:0034260, GO:2000502, GO:0006809, GO:0032729, GO:0045954, GO:0045429, GO:0007165, GO:0002223, GO:0031295, IPR001304, IPR016186, IPR016187, IPR042169, IPR033992, P26718",1,8EA6,mutant,P26718,UniProt,C29 H24 F6 N4 O2,574.517,VMH,"(4M)-N-{(1S)-2-(dimethylamino)-2-oxo-1-[3-(trifluoromethyl)phenyl]ethyl}-4-(1-methyl-1H-pyrazol-5-yl)-4'-(trifluoromethyl)[1,1'-biphenyl]-2-carboxamide",Cn1c(ccn1)c2ccc(c(c2)C(=O)NC(c3cccc(c3)C(F)(F)F)C(=O)N(C)C)c4ccc(cc4)C(F)(F)F,3
8EA6,,,,,,8EA6,Identification of small-molecule protein-protein interaction inhibitors for NKG2D.,NKG2D complexed with inhibitor 3e,IMMUNOSUPPRESSANT/INHIBITOR,"KLRK1, D12S2489E, NKG2D",,"GO:0009986, GO:0009897, GO:0005886, GO:0030246, GO:0042802, GO:0042288, GO:0032394, GO:0038023, GO:0002250, GO:0030154, GO:0071222, GO:0050830, GO:0030101, GO:0042267, GO:0034260, GO:2000502, GO:0006809, GO:0032729, GO:0045954, GO:0045429, GO:0007165, GO:0002223, GO:0031295, IPR001304, IPR016186, IPR016187, IPR042169, IPR033992, P26718",1,8EA6,mutant,P26718,UniProt,C24 H19 F6 N3 O2,495.417,VML,N-{(1S)-2-(dimethylamino)-2-oxo-1-[3-(trifluoromethyl)phenyl]ethyl}-4-[4-(trifluoromethyl)phenyl]pyridine-3-carboxamide,CN(C)C(=O)C(c1cccc(c1)C(F)(F)F)NC(=O)c2cnccc2c3ccc(cc3)C(F)(F)F,4
8EA9,,,,,,8EA9,Identification of small-molecule protein-protein interaction inhibitors for NKG2D.,NKG2D complexed with inhibitor 4d,IMMUNOSUPPRESSANT/INHIBITOR,"KLRK1, D12S2489E, NKG2D",,"GO:0009986, GO:0009897, GO:0005886, GO:0030246, GO:0042802, GO:0042288, GO:0032394, GO:0038023, GO:0002250, GO:0030154, GO:0071222, GO:0050830, GO:0030101, GO:0042267, GO:0034260, GO:2000502, GO:0006809, GO:0032729, GO:0045954, GO:0045429, GO:0007165, GO:0002223, GO:0031295, IPR001304, IPR016186, IPR016187, IPR042169, IPR033992, P26718",1,8EA9,mutant,P26718,UniProt,C25 H18 F9 N3 O2,563.415,VMQ,"N-[(1S)-1-[3,5-bis(trifluoromethyl)phenyl]-2-(dimethylamino)-2-oxoethyl]-4-[4-(trifluoromethyl)phenyl]pyridine-3-carboxamide",CN(C)C(=O)C(c1cc(cc(c1)C(F)(F)F)C(F)(F)F)NC(=O)c2cnccc2c3ccc(cc3)C(F)(F)F,3
8EAA,,,,,,8EAA,Identification of small-molecule protein-protein interaction inhibitors for NKG2D.,NKG2D complexed with inhibitor 4e,IMMUNOSUPPRESSANT/INHIBITOR,"KLRK1, D12S2489E, NKG2D",,"GO:0009986, GO:0009897, GO:0005886, GO:0030246, GO:0042802, GO:0042288, GO:0032394, GO:0038023, GO:0002250, GO:0030154, GO:0071222, GO:0050830, GO:0030101, GO:0042267, GO:0034260, GO:2000502, GO:0006809, GO:0032729, GO:0045954, GO:0045429, GO:0007165, GO:0002223, GO:0031295, IPR001304, IPR016186, IPR016187, IPR042169, IPR033992, P26718",1,8EAA,mutant,P26718,UniProt,C25 H21 F6 N3 O2,509.444,VMW,N-{(1S)-2-(dimethylamino)-1-[3-methyl-5-(trifluoromethyl)phenyl]-2-oxoethyl}-4-[4-(trifluoromethyl)phenyl]pyridine-3-carboxamide,Cc1cc(cc(c1)C(F)(F)F)C(C(=O)N(C)C)NC(=O)c2cnccc2c3ccc(cc3)C(F)(F)F,2
8EIT,,,,,,8EIT,Molecular mechanism of fatty acid activation of FFAR1.,Structure of FFAR1-Gq complex bound to DHA,MEMBRANE PROTEIN,,,,1,8EIT,wlidetype,,,C22 H32 O2,328.488,HXA,"DOCOSA-4,7,10,13,16,19-HEXAENOIC ACID",CCC=CCC=CCC=CCC=CCC=CCC=CCCC(=O)O,6
8EJC,,,,,,8EJC,Molecular mechanism of fatty acid activation of FFAR1.,Structure of FFAR1-Gq complex bound to TAK-875,MEMBRANE PROTEIN,,,,1,8EJC,wlidetype,,,C29 H32 O7 S,524.625,2YB,"[(3S)-6-({2',6'-dimethyl-4'-[3-(methylsulfonyl)propoxy]biphenyl-3-yl}methoxy)-2,3-dihydro-1-benzofuran-3-yl]acetic acid",Cc1cc(cc(c1c2cccc(c2)COc3ccc4c(c3)OCC4CC(=O)O)C)OCCCS(=O)(=O)C,6
8EJK,,,,,,8EJK,Molecular mechanism of fatty acid activation of FFAR1.,Structure of FFAR1-Gq complex bound to TAK-875 in a lipid nanodisc,MEMBRANE PROTEIN,,,,1,8EJK,wlidetype,,,C29 H32 O7 S,524.625,2YB,"[(3S)-6-({2',6'-dimethyl-4'-[3-(methylsulfonyl)propoxy]biphenyl-3-yl}methoxy)-2,3-dihydro-1-benzofuran-3-yl]acetic acid",Cc1cc(cc(c1c2cccc(c2)COc3ccc4c(c3)OCC4CC(=O)O)C)OCCCS(=O)(=O)C,6
8EMS,,,,,,8EMS,Cryo-EM structure of human liver glycogen phosphorylase,Cryo-EM structure of human liver glycogen phosphorylase,HYDROLASE,PYGL,2.4.1.1,"GO:0005737, GO:0005829, GO:0070062, GO:0005576, GO:1904813, GO:0034774, GO:0016208, GO:0005524, GO:0032052, GO:0005536, GO:0008184, GO:0042802, GO:0102250, GO:0002060, GO:0030170, GO:0102499, GO:0019842, GO:0006015, GO:0042593, GO:0005980, GO:0005977, GO:0070266, GO:0009617, IPR011833, IPR000811, IPR035090, P06737",1,8EMS,wlidetype,P06737,UniProt,C8 H10 N O6 P,247.142,PLP,PYRIDOXAL-5'-PHOSPHATE,Cc1c(c(c(cn1)COP(=O)(O)O)C=O)O,2
8EMT,,,,,,8EMT,Cryo-EM analysis of the human aldehyde oxidase from liver,Cryo-EM analysis of the human aldehyde oxidase from liver,OXIDOREDUCTASE,"AOX1, AO","1.2.3.1, 1.17.3","GO:0005829, GO:0070062, GO:0051537, GO:0004031, GO:0071949, GO:0050660, GO:0042802, GO:0005506, GO:0043546, GO:0051287, GO:0016491, GO:0042803, GO:0006629, GO:0006805, IPR002888, IPR036884, IPR036010, IPR001041, IPR006058, IPR000674, IPR036856, IPR016208, IPR014313, IPR008274, IPR037165, IPR012675, IPR005107, IPR036683, IPR016166, IPR036318, IPR016167, IPR016169, IPR002346, IPR022407, Q06278",1,8EMT,wlidetype,Q06278,UniProt,C27 H33 N9 O15 P2,785.55,FAD,FLAVIN-ADENINE DINUCLEOTIDE,Cc1cc2c(cc1C)N(C3=NC(=O)NC(=O)C3=N2)CC(C(C(COP(=O)(O)OP(=O)(O)OCC4C(C(C(O4)n5cnc6c5ncnc6N)O)O)O)O)O,5
8ET7,,,,,,8ET7,Molecular basis of polyspecific drug binding and transport by OCT1 and OCT2.,Cryo-EM structure of the organic cation transporter 1 in complex with diphenhydramine,TRANSPORT PROTEIN,,,,1,8ET7,wlidetype,,,C17 H21 N O,255.355,2PM,"N-[2-(BENZHYDRYLOXY)ETHYL]-N,N-DIMETHYLAMINE",CN(C)CCOC(c1ccccc1)c2ccccc2,3
8ET8,,,,,,8ET8,Molecular basis of polyspecific drug binding and transport by OCT1 and OCT2.,Cryo-EM structure of the organic cation transporter 1 in complex with verapamil,TRANSPORT PROTEIN,,,,1,8ET8,wlidetype,,,C27 H38 N2 O4,454.602,4YH,"(2S)-2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile",CC(C)C(CCCN(C)CCc1ccc(c(c1)OC)OC)(C#N)c2ccc(c(c2)OC)OC,3
8ET9,,,,,,8ET9,Molecular basis of polyspecific drug binding and transport by OCT1 and OCT2.,Cryo-EM structure of the organic cation transporter 2 in complex with 1-methyl-4-phenylpyridinium,TRANSPORT PROTEIN,,,,1,8ET9,wlidetype,,,C12 H12 N,170.23,WRF,1-methyl-4-phenylpyridin-1-ium,C[n+]1ccc(cc1)c2ccccc2,2
8EX4,,,,,,8EX4,Structural and functional insights into Spns2-mediated transport of sphingosine-1-phosphate.,Human S1P transporter Spns2 in an inward-facing open conformation (state 1),MEMBRANE PROTEIN,SPNS2,,"GO:0010008, GO:0016020, GO:0005886, GO:0046624, GO:0022857, GO:0001782, GO:0060348, GO:0006869, GO:0048535, GO:0072676, GO:0048073, GO:0002920, GO:2000404, GO:0007605, GO:0030148, GO:0003376, GO:0043029, IPR011701, IPR020846, IPR044770, IPR036259, Q8IVW8, Transmembrane.Alpha-helical polytopic.Major Facilitator Superfamily (MFS).Spinster protein family, Generic PDBTM",1,8EX4,wlidetype,Q8IVW8,UniProt,C18 H38 N O5 P,379.472,S1P,"(2S,3R,4E)-2-amino-3-hydroxyoctadec-4-en-1-yl dihydrogen phosphate",CCCCCCCCCCCCCC=CC(C(COP(=O)(O)O)N)O,2
8EX6,,,,,,8EX6,Structural and functional insights into Spns2-mediated transport of sphingosine-1-phosphate.,Human S1P transporter Spns2 in an inward-facing open conformation (state 1*),MEMBRANE PROTEIN,SPNS2,,"GO:0010008, GO:0016020, GO:0005886, GO:0046624, GO:0022857, GO:0001782, GO:0060348, GO:0006869, GO:0048535, GO:0072676, GO:0048073, GO:0002920, GO:2000404, GO:0007605, GO:0030148, GO:0003376, GO:0043029, IPR011701, IPR020846, IPR044770, IPR036259, Q8IVW8, Transmembrane.Alpha-helical polytopic.Major Facilitator Superfamily (MFS).Spinster protein family, Generic PDBTM",1,8EX6,wlidetype,Q8IVW8,UniProt,C18 H38 N O5 P,379.472,S1P,"(2S,3R,4E)-2-amino-3-hydroxyoctadec-4-en-1-yl dihydrogen phosphate",CCCCCCCCCCCCCC=CC(C(COP(=O)(O)O)N)O,2
8F93,,,,,,8F93,Direct mapping of ligandable tyrosines and lysines in cells with chiral sulfonyl fluoride probes,WDR5 covalently modified at Y228 by (R)-2-SF,GENE REGULATION/INHIBITOR,"WDR5, BIG3",,"GO:0140672, GO:0000123, GO:0035097, GO:0072686, GO:0071339, GO:0044665, GO:0044666, GO:0044545, GO:0005654, GO:0005634, GO:0048188, GO:0042393, GO:0035064, GO:0006325, GO:0006094, GO:0043966, GO:0044154, GO:0051568, GO:0043984, GO:0043981, GO:0043982, GO:0051572, GO:0031175, GO:0045722, GO:0051571, GO:0045893, GO:0051726, GO:0051302, GO:1900095, GO:0045995, GO:0031063, GO:0006357, GO:0006355, GO:0090043, GO:0001501, IPR020472, IPR015943, IPR001680, IPR019775, IPR036322, P61964",1,8F93,wlidetype,P61964,UniProt,C30 H29 F N4 O4 S,560.639,XKN,3-ethynyl-5-{[(3R)-4-{1-[(2-methoxyphenyl)methyl]-1H-benzimidazole-5-carbonyl}-3-methylpiperazin-1-yl]methyl}benzene-1-sulfonyl fluoride,CC1CN(CCN1C(=O)c2ccc3c(c2)ncn3Cc4ccccc4OC)Cc5cc(cc(c5)S(=O)(=O)F)C#C,2
8FNY,,,,,,8FNY,ADP enhances the allosteric activation of eukaryotic elongation factor 2 kinase by calmodulin.,Nucleotide-bound structure of a functional construct of eukaryotic elongation factor 2 kinase.,TRANSLATION/Transferase,EEF2K,2.7.11.20,"GO:0005737, GO:0005829, GO:0043197, GO:0014069, GO:0005524, GO:0005509, GO:0005516, GO:0004686, GO:0004672, GO:0004674, GO:0008135, GO:0071454, GO:1990416, GO:0071277, GO:0071320, GO:0032869, GO:0043066, GO:0061003, GO:0045807, GO:0051965, GO:0046777, GO:0031952, GO:0002931, GO:1990637, GO:0006414, IPR017400, IPR011009, IPR004166, IPR006597, IPR011990, O00418",1,8FNY,wlidetype,O00418,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,3
8FNY,,,,,,8FNY,ADP enhances the allosteric activation of eukaryotic elongation factor 2 kinase by calmodulin.,Nucleotide-bound structure of a functional construct of eukaryotic elongation factor 2 kinase.,TRANSLATION/Transferase,EEF2K,2.7.11.20,"GO:0005737, GO:0005829, GO:0043197, GO:0014069, GO:0005524, GO:0005509, GO:0005516, GO:0004686, GO:0004672, GO:0004674, GO:0008135, GO:0071454, GO:1990416, GO:0071277, GO:0071320, GO:0032869, GO:0043066, GO:0061003, GO:0045807, GO:0051965, GO:0046777, GO:0031952, GO:0002931, GO:1990637, GO:0006414, IPR017400, IPR011009, IPR004166, IPR006597, IPR011990, O00418",1,8FNY,wlidetype,O00418,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,4
8FO3,,,,,,8FO3,Crystal Structures of Diaryl Hydrazone and Sulfone Stabilizers in Complex with an Amyloidogenic Light Chain Reveal an Alternate Ligand-Binding Cavity,Structure of full-length amyloidogenic immunoglobulin light chain H9 in complex with (E)-3-nitro-4-(2-(2-phenylpropylidene)hydrazineyl)benzenesulfonamide,IMMUNE SYSTEM,,,,1,8FO3,wlidetype,,,C15 H18 N4 O4 S,350.393,Y4K,3-nitro-4-{2-[(2S)-2-phenylpropyl]hydrazinyl}benzene-1-sulfonamide,CC(CNNc1ccc(cc1N(=O)=O)S(=O)(=O)N)c2ccccc2,2
8FO4,,,,,,8FO4,Crystal Structures of Diaryl Hydrazone and Sulfone Stabilizers in Complex with an Amyloidogenic Light Chain Reveal an Alternate Ligand-Binding Cavity,"Structure of full-length amyloidogenic immunoglobulin light chain H9 in complex with 6-methyl-2-(2-((1E,2E)-3-(2-nitrophenyl)allylidene)hydrazineyl)pyrimidin-4-ol",IMMUNE SYSTEM,,,,1,8FO4,wlidetype,,,C14 H15 N5 O3,301.301,Y4Q,6-methyl-2-{2-[(1E)-3-(2-nitrophenyl)prop-1-en-1-yl]hydrazinyl}pyrimidin-4(5H)-one,CC1=NC(=NC(=O)C1)NNC=CCc2ccccc2N(=O)=O,2
8FO5,,,,,,8FO5,Crystal Structures of Diaryl Hydrazone and Sulfone Stabilizers in Complex with an Amyloidogenic Light Chain Reveal an Alternate Ligand-Binding Cavity,Structure of full-length amyloidogenic immunoglobulin light chain H9 in complex with 1-(1-(phenylsulfonyl)-1H-pyrrol-3-yl)ethan-1-one,IMMUNE SYSTEM,,,,1,8FO5,wlidetype,,,C12 H11 N O3 S,249.286,Y4U,1-[1-(benzenesulfonyl)-1H-pyrrol-3-yl]ethan-1-one,CC(=O)c1ccn(c1)S(=O)(=O)c2ccccc2,2
8G0L,,,,,,8G0L,Semi-synthetic CoA-alpha-Synuclein Constructs Trap N-terminal Acetyltransferase NatB for Binding Mechanism Studies.,Semi-synthetic CoA-alpha-Synuclein Constructs Trap N-terminal Acetyltransferase NatB for Binding Mechanism Studies,TRANSFERASE,"NAA20, NAT5",2.3.1.254,"GO:0005737, GO:0005829, GO:0031416, GO:0005634, GO:0004596, GO:0017196, IPR016181, IPR000182, P61599",1,8G0L,wlidetype,P61599,UniProt,C23 H38 N7 O18 P3 S,825.57,CMC,CARBOXYMETHYL COENZYME *A,CC(C)(COP(=O)(O)OP(=O)(O)OCC1C(C(C(O1)n2cnc3c2ncnc3N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSCC(=O)O)O,4
8G1E,,,,,,8G1E,Allosteric role of the citrate synthase homology domain of ATP citrate lyase.,Structure of ACLY-D1026A-products-asym,TRANSFERASE,ACLY,2.3.3.8,"GO:0035578, GO:0005829, GO:0070062, GO:0005576, GO:1904813, GO:0016020, GO:0005654, GO:0005524, GO:0003878, GO:0046872, GO:0006085, GO:0006695, GO:0006101, GO:0015936, GO:0006633, GO:0008610, GO:0006107, IPR014608, IPR017440, IPR032263, IPR016143, IPR002020, IPR036969, IPR033847, IPR003781, IPR005811, IPR036291, IPR017866, IPR016102, P53396",1,8G1E,mutant,P53396,UniProt,,,UNL,Unknown ligand,,4
8G1F,,,,,,8G1F,Allosteric role of the citrate synthase homology domain of ATP citrate lyase.,Structure of ACLY-D1026A-products,LYASE,ACLY,2.3.3.8,"GO:0035578, GO:0005829, GO:0070062, GO:0005576, GO:1904813, GO:0016020, GO:0005654, GO:0005524, GO:0003878, GO:0046872, GO:0006085, GO:0006695, GO:0006101, GO:0015936, GO:0006633, GO:0008610, GO:0006107, IPR014608, IPR017440, IPR032263, IPR016143, IPR002020, IPR036969, IPR033847, IPR003781, IPR005811, IPR036291, IPR017866, IPR016102, P53396",1,8G1F,mutant,P53396,UniProt,,,UNL,Unknown ligand,,3
8G2Y,,,,,,8G2Y,Tethered agonist activated ADGRF1 structure and signalling analysis reveal basis for G protein coupling.,Cryo-EM structure of ADGRF1 coupled to miniGs/q,SIGNALING PROTEIN,GNG2,,"GO:0070062, GO:0005834, GO:0016020, GO:0005886, GO:0031681, GO:0007191, GO:0071870, GO:0071380, GO:0048144, GO:0007186, IPR015898, IPR036284, IPR001770, P59768, Transmembrane.Alpha-helical polytopic.Rhodopsin-like receptors and pumps.GPCR Secretin (B) family, Generic PDBTM",3,8G2Y,wlidetype,P59768,UniProt,C22 H47 N O7 P,468.585,LPC,[1-MYRISTOYL-GLYCEROL-3-YL]PHOSPHONYLCHOLINE,CCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)OCC[N+](C)(C)C)O,6
8G3S,,,,,,8G3S,"Discovery of an Oral, Beyond-Rule-of-Five Mcl-1 Protein-Protein Interaction Modulator with the Potential of Treating Hematological Malignancies.",MBP-Mcl1 in complex with ligand 11,APOPTOSIS,"malE, JW3994",,"GO:0097136, GO:0005737, GO:0005829, GO:0016020, GO:0005741, GO:0005739, GO:0005654, GO:0005634, GO:0051434, GO:0046982, GO:0042803, GO:0008320, GO:0001709, GO:0019725, GO:0097192, GO:0008630, GO:2000811, GO:0043066, GO:0010507, GO:2001240, GO:2001243, GO:0043065, GO:1903378, GO:0042981, GO:0034097, IPR013281, IPR036834, IPR046371, IPR026298, IPR002475, IPR020717, IPR020726, IPR020728, GO:0042597, GO:0015144, IPR036736, IPR006060, IPR009081, IPR006059, IPR006061, Q07820",1,8G3S,wlidetype,A0A4P1LXE0,UniProt,C33 H41 Cl N2 O6 S,629.206,YLT,"(1'S,3aS,5R,16R,17S,19E,21S,21aR)-6'-chloro-21-methoxy-16,17-dimethyl-2,3,3',3a,4',16,17,18,21,21a-decahydro-2'H,6H,8H-15lambda~6~-spiro[10,12-etheno-15lambda~6~-furo[3,2-i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-7,1'-naphthalene]-13,15,15(4H,14H)-trione",CC1CC=CC(C2C(CCO2)CN3CC4(CCCc5c4ccc(c5)Cl)COc6c3cc(cc6)C(=O)NS(=O)(=O)C1C)OC,4
8G3T,,,,,,8G3T,"Discovery of an Oral, Beyond-Rule-of-Five Mcl-1 Protein-Protein Interaction Modulator with the Potential of Treating Hematological Malignancies.",MBP-Mcl1 in complex with ligand 12,APOPTOSIS,"malE, JW3994",,"GO:0097136, GO:0005737, GO:0005829, GO:0016020, GO:0005741, GO:0005739, GO:0005654, GO:0005634, GO:0051434, GO:0046982, GO:0042803, GO:0008320, GO:0001709, GO:0019725, GO:0097192, GO:0008630, GO:2000811, GO:0043066, GO:0010507, GO:2001240, GO:2001243, GO:0043065, GO:1903378, GO:0042981, GO:0034097, IPR013281, IPR036834, IPR046371, IPR026298, IPR002475, IPR020717, IPR020726, IPR020728, GO:0042597, GO:0015144, IPR036736, IPR006060, IPR009081, IPR006059, IPR006061, Q07820",1,8G3T,wlidetype,A0A4P1LXE0,UniProt,C33 H40 Cl F N2 O6 S,647.197,YLK,"(1'S,3aS,5R,16R,17S,19Z,21R,21aR)-6'-chloro-20-fluoro-21-methoxy-16,17-dimethyl-2,3,3',3a,4',16,17,18,21,21a-decahydro-2'H,6H,8H-15lambda~6~-spiro[10,12-etheno-15lambda~6~-furo[3,2-i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-7,1'-naphthalene]-13,15,15(4H,14H)-trione",CC1CC=C(C(C2C(CCO2)CN3CC4(CCCc5c4ccc(c5)Cl)COc6c3cc(cc6)C(=O)NS(=O)(=O)C1C)OC)F,5
8G3W,,,,,,8G3W,"Discovery of an Oral, Beyond-Rule-of-Five Mcl-1 Protein-Protein Interaction Modulator with the Potential of Treating Hematological Malignancies.",MBP-Mcl1 in complex with ligand 28,APOPTOSIS,"malE, JW3994",,"GO:0097136, GO:0005737, GO:0005829, GO:0016020, GO:0005741, GO:0005739, GO:0005654, GO:0005634, GO:0051434, GO:0046982, GO:0042803, GO:0008320, GO:0001709, GO:0019725, GO:0097192, GO:0008630, GO:2000811, GO:0043066, GO:0010507, GO:2001240, GO:2001243, GO:0043065, GO:1903378, GO:0042981, GO:0034097, IPR013281, IPR036834, IPR046371, IPR026298, IPR002475, IPR020717, IPR020726, IPR020728, GO:0042597, GO:0015144, IPR036736, IPR006060, IPR009081, IPR006059, IPR006061, Q07820",1,8G3W,wlidetype,A0A4P1LXE0,UniProt,C38 H45 Cl F N5 O7 S,770.31,YKX,"N-[(1'S,3aS,5R,15S,17S,19Z,21R,21aR)-6'-chloro-20-fluoro-21-methoxy-17-methyl-13,15-dioxo-2,3,3',3a,4,4',13,16,17,18,21,21a-dodecahydro-2'H,6H,8H-15lambda~6~-spiro[10,12-(ethanediylidene)-15lambda~6~-furo[3,2-i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-7,1'-naphthalen]-15-yl]-3-methoxy-1-methyl-1H-pyrazole-4-carboxamide",CC1CC=C(C(C2C(CCO2)CN3CC4(CCCc5c4ccc(c5)Cl)COc6c3cc(cc6)C(=O)N=S(=O)(C1)NC(=O)c7cn(nc7OC)C)OC)F,5
8G3Y,,,,,,8G3Y,"Discovery of an Oral, Beyond-Rule-of-Five Mcl-1 Protein-Protein Interaction Modulator with the Potential of Treating Hematological Malignancies.",MBP-Mcl1 in complex with ligand 34,APOPTOSIS,"malE, JW3994",,"GO:0097136, GO:0005737, GO:0005829, GO:0016020, GO:0005741, GO:0005739, GO:0005654, GO:0005634, GO:0051434, GO:0046982, GO:0042803, GO:0008320, GO:0001709, GO:0019725, GO:0097192, GO:0008630, GO:2000811, GO:0043066, GO:0010507, GO:2001240, GO:2001243, GO:0043065, GO:1903378, GO:0042981, GO:0034097, IPR013281, IPR036834, IPR046371, IPR026298, IPR002475, IPR020717, IPR020726, IPR020728, GO:0042597, GO:0015144, IPR036736, IPR006060, IPR009081, IPR006059, IPR006061, Q07820",1,8G3Y,wlidetype,A0A4P1LXE0,UniProt,C46 H59 Cl F N7 O8 S,924.519,YKL,"N-[(1'S,3aS,5R,15S,17S,19Z,21S,21aR)-6'-chloro-20-fluoro-21-{[(5S,9aS)-hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]methyl}-21-methoxy-17-methyl-13,15-dioxo-2,3,3',3a,4,4',13,16,17,18,21,21a-dodecahydro-2'H,6H,8H-15lambda~6~-spiro[10,12-(ethanediylidene)-15lambda~6~-furo[3,2-i][1,4]oxazepino[3,4-f][1,2,7]thiadiazacyclohexadecine-7,1'-naphthalen]-15-yl]-3-methoxy-1-methyl-1H-pyrazole-4-carboxamide",CC1CC=C(C(C2C(CCO2)CN3CC4(CCCc5c4ccc(c5)Cl)COc6c3cc(cc6)C(=O)N=S(=O)(C1)NC(=O)c7cn(nc7OC)C)(CN8CCN9CCOCC9C8)OC)F,6
8G5C,,,,,,8G5C,Allosteric role of the citrate synthase homology domain of ATP citrate lyase.,"Structure of ACLY-D1026A-substrates, local refinement of ASH domain",TRANSFERASE,ACLY,2.3.3.8,"GO:0035578, GO:0005829, GO:0070062, GO:0005576, GO:1904813, GO:0016020, GO:0005654, GO:0005524, GO:0003878, GO:0046872, GO:0006085, GO:0006695, GO:0006101, GO:0015936, GO:0006633, GO:0008610, GO:0006107, IPR014608, IPR017440, IPR032263, IPR016143, IPR002020, IPR036969, IPR033847, IPR003781, IPR005811, IPR036291, IPR017866, IPR016102, P53396",1,8G5C,mutant,P53396,UniProt,C27 H42 N7 O22 P3 S,941.642,Q5B,(3S)-citryl-Coenzyme A,CC(C)(COP(=O)(O)OP(=O)(O)OCC1C(C(C(O1)n2cnc3c2ncnc3N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)CC(CC(=O)O)(C(=O)O)O)O,6
8G5D,,,,,,8G5D,Allosteric role of the citrate synthase homology domain of ATP citrate lyase.,"Structure of ACLY-D1026A-products, local refinement of ASH domain",TRANSFERASE,ACLY,2.3.3.8,"GO:0035578, GO:0005829, GO:0070062, GO:0005576, GO:1904813, GO:0016020, GO:0005654, GO:0005524, GO:0003878, GO:0046872, GO:0006085, GO:0006695, GO:0006101, GO:0015936, GO:0006633, GO:0008610, GO:0006107, IPR014608, IPR017440, IPR032263, IPR016143, IPR002020, IPR036969, IPR033847, IPR003781, IPR005811, IPR036291, IPR017866, IPR016102, P53396",1,8G5D,mutant,P53396,UniProt,C27 H42 N7 O22 P3 S,941.642,Q5B,(3S)-citryl-Coenzyme A,CC(C)(COP(=O)(O)OP(=O)(O)OCC1C(C(C(O1)n2cnc3c2ncnc3N)O)OP(=O)(O)O)C(C(=O)NCCC(=O)NCCSC(=O)CC(CC(=O)O)(C(=O)O)O)O,4
8G92,,,,,,8G92,Mechanisms and Inhibition of Spns2-mediated transport of sphingosine-1-phosphate,Structure of inhibitor 16d-bound SPNS2,IMMUNE SYSTEM,SPNS2,,"GO:0010008, GO:0016020, GO:0005886, GO:0046624, GO:0022857, GO:0001782, GO:0060348, GO:0006869, GO:0048535, GO:0072676, GO:0048073, GO:0002920, GO:2000404, GO:0007605, GO:0030148, GO:0003376, GO:0043029, IPR011701, IPR020846, IPR044770, IPR036259, Q8IVW8, Transmembrane.Alpha-helical polytopic.Major Facilitator Superfamily (MFS).Spinster protein family, Generic PDBTM",1,8G92,wlidetype,Q8IVW8,UniProt,C21 H33 N3 O,343.506,YUX,"3-[3-(4-decylphenyl)-1,2,4-oxadiazol-5-yl]propan-1-amine",CCCCCCCCCCc1ccc(cc1)c2nc(on2)CCCN,2
8GHF,,,,,,8GHF,Membrane protein isolation and structure determination in cell-derived membrane vesicles.,cryo-EM structure of hSlo1 in plasma membrane vesicles,TRANSPORT PROTEIN,KCNMA1,,"GO:0016324, GO:0005901, GO:0005886, GO:0045211, GO:0008076, GO:0003779, GO:0015269, GO:0042802, GO:0060072, GO:0046872, GO:0005249, GO:0030007, GO:0060073, GO:0045794, GO:0043065, GO:0006813, GO:0034765, GO:0042391, GO:0060087, GO:0051592, GO:0034465, GO:0001666, GO:0006970, GO:0060083, IPR024939, IPR005821, IPR003929, IPR036291, Q12791, TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.Channels: Potassium, Sodium, & Proton Ion-Selective.Human BK (SLO1) K<sup>+</sup> channel in total membrane vesicles, Ca<sup>2+</sup>-free and EDTA-free, Transmembrane.Alpha-helical polytopic.Ion channel (VIC) superfamily.Slo potassium channels, Generic PDBTM",1,8GHF,wlidetype,Q12791,UniProt,C42 H82 N O8 P,760.076,POV,(2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate,CCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC,4
8GHF,,,,,,8GHF,Membrane protein isolation and structure determination in cell-derived membrane vesicles.,cryo-EM structure of hSlo1 in plasma membrane vesicles,TRANSPORT PROTEIN,KCNMA1,,"GO:0016324, GO:0005901, GO:0005886, GO:0045211, GO:0008076, GO:0003779, GO:0015269, GO:0042802, GO:0060072, GO:0046872, GO:0005249, GO:0030007, GO:0060073, GO:0045794, GO:0043065, GO:0006813, GO:0034765, GO:0042391, GO:0060087, GO:0051592, GO:0034465, GO:0001666, GO:0006970, GO:0060083, IPR024939, IPR005821, IPR003929, IPR036291, Q12791, TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.Channels: Potassium, Sodium, & Proton Ion-Selective.Human BK (SLO1) K<sup>+</sup> channel in total membrane vesicles, Ca<sup>2+</sup>-free and EDTA-free, Transmembrane.Alpha-helical polytopic.Ion channel (VIC) superfamily.Slo potassium channels, Generic PDBTM",1,8GHF,wlidetype,Q12791,UniProt,C27 H46 O,386.654,CLR,CHOLESTEROL,CC(C)CCCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C,5
8GM4,,,,,,8GM4,Structure of the complex between calmodulin and a functional construct of eukaryotic elongation factor 2 kinase bound to an ATP-competitive inhibitor.,Functional construct of the Eukaryotic elongation factor 2 kinase bound to an ATP-competitive inhibitor,TRANSLATION/Transferase,EEF2K,2.7.11.20,"GO:0005737, GO:0005829, GO:0043197, GO:0014069, GO:0005524, GO:0005509, GO:0005516, GO:0004686, GO:0004672, GO:0004674, GO:0008135, GO:0071454, GO:1990416, GO:0071277, GO:0071320, GO:0032869, GO:0043066, GO:0061003, GO:0045807, GO:0051965, GO:0046777, GO:0031952, GO:0002931, GO:1990637, GO:0006414, IPR017400, IPR011009, IPR004166, IPR006597, IPR011990, O00418",1,8GM4,wlidetype,O00418,UniProt,C13 H15 N5 O3,289.29,EKI,"7-amino-1-cyclopropyl-3-ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-6-carboxamide",CCN1C(=O)c2cc(c(nc2N(C1=O)C3CC3)N)C(=O)N,4
8GS8,,,,,,8GS8,Structure of the human respiratory complex II.,cryo-EM structure of the human respiratory complex II,OXIDOREDUCTASE,"SDHA, SDH2, SDHF",1.3.5.1,"GO:0005743, GO:0005749, GO:0005739, GO:0005730, GO:0009055, GO:0050660, GO:0008177, GO:0006121, GO:0007399, GO:0042776, GO:0022904, GO:0006105, GO:0006099, IPR003953, IPR036188, IPR003952, IPR037099, IPR015939, IPR030664, IPR027477, IPR011281, IPR014006, P31040, Transmembrane.Alpha-helical polytopic.Electron transport chain complex II superfamily.Succinate dehydrogenase/fumarate reductase, Generic PDBTM",1,8GS8,wlidetype,P31040,UniProt,C34 H32 Fe N4 O4,616.487,HEM,PROTOPORPHYRIN IX CONTAINING FE,Cc1c2n3c(c1CCC(=O)O)C=C4C(=C(C5=[N]4[Fe]36[N]7=C(C=C8N6C(=C5)C(=C8C)C=C)C(=C(C7=C2)C)C=C)C)CCC(=O)O,10
8GS8,,,,,,8GS8,Structure of the human respiratory complex II.,cryo-EM structure of the human respiratory complex II,OXIDOREDUCTASE,"SDHC, CYB560, SDH3",,"GO:0016020, GO:0005743, GO:0005749, GO:0005739, GO:0009055, GO:0020037, GO:0046872, GO:0000104, GO:0009060, GO:0006121, GO:0042776, GO:0006099, IPR034804, IPR018495, IPR014314, IPR000701, Q99643, Transmembrane.Alpha-helical polytopic.Electron transport chain complex II superfamily.Succinate dehydrogenase/fumarate reductase, Generic PDBTM",3,8GS8,wlidetype,Q99643,UniProt,C27 H33 N9 O15 P2,785.55,FAD,FLAVIN-ADENINE DINUCLEOTIDE,Cc1cc2c(cc1C)N(C3=NC(=O)NC(=O)C3=N2)CC(C(C(COP(=O)(O)OP(=O)(O)OCC4C(C(C(O4)n5cnc6c5ncnc6N)O)O)O)O)O,5
8GUQ,,,,,,8GUQ,Structural basis of selective cannabinoid CB 2 receptor activation.,Cryo-EM structure of CB2-G protein complex,STRUCTURAL PROTEIN,GNG2,,"GO:0070062, GO:0005834, GO:0016020, GO:0005886, GO:0031681, GO:0007191, GO:0071870, GO:0071380, GO:0048144, GO:0007186, IPR015898, IPR036284, IPR001770, P59768, TRANSMEMBRANE PROTEINS: ALPHA-HELICAL.G Protein-Coupled Receptors: Class A.CB<sub>2</sub>-G<sub>i</sub> cannabinoid receptor complex with bound LEI-102, Transmembrane.Alpha-helical polytopic.Rhodopsin-like receptors and pumps.G-protein coupled receptors, family A, Generic PDBTM",3,8GUQ,wlidetype,P59768,UniProt,C18 H23 N5 O3,357.407,KNF,"(2~{S},4~{S})-~{N}-[(2~{S})-3,3-dimethyl-1-oxidanyl-butan-2-yl]-9-(4-oxidanylpyrazin-2-yl)-8,9-diazatricyclo[4.3.0.0^{2,4}]nona-1(6),7-diene-7-carboxamide",CC(C)(C)C(CO)NC(=O)c1c2c(n(n1)c3c[n+](ccn3)[O-])C4CC4C2,6
8GUW,,,,,,8GUW,Structural basis for CEP192-mediated regulation of centrosomal AURKA.,Structure of Aurora Kinase A in complex with activator peptide,CYTOSOLIC PROTEIN,"CEP192, KIAA1569, PP8407",2.7.11.1,"GO:0005814, GO:0005813, GO:0005737, GO:0005829, GO:0000242, GO:0120098, GO:0120099, GO:0019902, GO:0019901, GO:0007099, GO:0090222, GO:0090307, GO:0071539, GO:0009617, IPR013783, IPR039103, GO:0043203, GO:0032133, GO:0036064, GO:0042585, GO:0072687, GO:0005874, GO:0015630, GO:0030496, GO:0072686, GO:0097431, GO:0005654, GO:0005634, GO:0048471, GO:0045120, GO:0005819, GO:0051233, GO:0031616, GO:0005524, GO:0046982, GO:0004672, GO:0106310, GO:0004674, GO:0004712, GO:0031625, GO:0009948, GO:0006915, GO:0051301, GO:0051642, GO:0061523, GO:0000086, GO:0097421, GO:0000278, GO:0007100, GO:0007052, GO:0043066, GO:0010629, GO:0032091, GO:1990138, GO:0018105, GO:0090141, GO:0045840, GO:1900195, GO:0032436, GO:0043161, GO:0046777, GO:0006468, GO:0046605, GO:0032465, GO:0010389, GO:0031647, GO:1901796, GO:0009611, GO:0007057, GO:0007051, IPR030616, IPR030611, IPR011009, IPR000719, IPR017441, IPR008271, Q8TEP8, O14965",1,8GUW,mutant,Q8TEP8,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,2
8GZE,,,,,,8GZE,Crystal Structure of METTL9-SAH-SLC39A7 peptide,Crystal Structure of human METTL9-SAH-SLC39A7 peptide complex,TRANSFERASE,"METTL9, DREV, CGI-81",2.1.1,"GO:0005783, GO:0005739, GO:0106370, IPR007884, IPR029063, Q9H1A3",1,8GZE,wlidetype,Q9H1A3,UniProt,C14 H20 N6 O5 S,384.411,SAH,S-ADENOSYL-L-HOMOCYSTEINE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)CSCCC(C(=O)O)N)O)O)N,3
8H07,,,,,,8H07,Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants.,SARS-CoV-2 BA.4 variants S ectodomain trimer in complex with neutralizing antibody 10-5B and 6-2C,VIRAL PROTEIN/IMMUNE SYSTEM,"S, 2",,"GO:0044173, GO:0020002, GO:0016020, GO:0019031, GO:0055036, GO:0046789, GO:0042802, GO:0075509, GO:0039654, GO:0019064, GO:0061025, GO:0046598, GO:0019065, GO:0046813, GO:0039587, GO:0039502, GO:0046718, GO:0019058, IPR032500, IPR042578, IPR043607, IPR043473, IPR043002, IPR044341, IPR018548, IPR044366, IPR036326, IPR002552, IPR044873, IPR044874, P0DTC2",1,8H07,mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,6
8H08,,,,,,8H08,Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants.,SARS-CoV-2 BA.1 variants S ectodomain trimer in complex with neutralizing antibody 10-5B and 6-2C,VIRAL PROTEIN/IMMUNE SYSTEM,"S, 2",,"GO:0044173, GO:0020002, GO:0016020, GO:0019031, GO:0055036, GO:0046789, GO:0042802, GO:0075509, GO:0039654, GO:0019064, GO:0061025, GO:0046598, GO:0019065, GO:0046813, GO:0039587, GO:0039502, GO:0046718, GO:0019058, IPR032500, IPR042578, IPR043607, IPR043473, IPR043002, IPR044341, IPR018548, IPR044366, IPR036326, IPR002552, IPR044873, IPR044874, P0DTC2",1,8H08,mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,6
8H9E,,,,,,8H9E,Structure of the human ATP synthase.,"Human ATP synthase F1 domain, state 1",MEMBRANE PROTEIN,"ATP5F1B, ATP5B, ATPMB, ATPSB",7.1.2.2,"GO:0009986, GO:0070062, GO:0016020, GO:0005743, GO:0005759, GO:0031966, GO:0042645, GO:0005753, GO:0005754, GO:0005739, GO:0005634, GO:0005886, GO:0045259, GO:0045261, GO:0043532, GO:0005524, GO:0042288, GO:0046933, GO:0046961, GO:0001525, GO:0006754, GO:0098761, GO:0006091, GO:0006629, GO:0006933, GO:0001649, GO:0043536, GO:0015986, GO:0042776, GO:1902600, GO:0051453, IPR003593, IPR005722, IPR020003, IPR004100, IPR036121, IPR000194, IPR024034, IPR027417, P06576",2,8H9E,wlidetype,P06576,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,8
8H9E,,,,,,8H9E,Structure of the human ATP synthase.,"Human ATP synthase F1 domain, state 1",MEMBRANE PROTEIN,"ATP5F1C, ATP5C, ATP5C1, ATP5CL1",,"GO:0016020, GO:0005743, GO:0005759, GO:0005753, GO:0000275, GO:0005739, GO:0046933, GO:0003723, GO:0006754, GO:0006119, GO:0015986, GO:0042776, IPR035968, IPR000131, IPR023632, P36542",3,8H9E,wlidetype,P36542,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,6
8H9I,,,,,,8H9I,Structure of the human ATP synthase.,"Human ATP synthase F1 domain, state2",MEMBRANE PROTEIN,"ATP5F1A, ATP5A, ATP5A1, ATP5AL2, ATPM",,"GO:0009986, GO:0070062, GO:0016020, GO:0045121, GO:0005743, GO:0005759, GO:0005753, GO:0005754, GO:0005739, GO:0005634, GO:0005886, GO:0045259, GO:0045261, GO:0043531, GO:0043532, GO:0005524, GO:0016887, GO:0042288, GO:0002020, GO:0046933, GO:0003723, GO:0006915, GO:0006754, GO:0071549, GO:0071732, GO:0006629, GO:0001937, GO:0043536, GO:0015986, GO:0042776, GO:0045471, GO:0014850, IPR023366, IPR000793, IPR038376, IPR033732, IPR005294, IPR020003, IPR004100, IPR036121, IPR000194, IPR027417, P25705",1,8H9I,wlidetype,P25705,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,5
8H9I,,,,,,8H9I,Structure of the human ATP synthase.,"Human ATP synthase F1 domain, state2",MEMBRANE PROTEIN,"ATP5F1C, ATP5C, ATP5C1, ATP5CL1",,"GO:0016020, GO:0005743, GO:0005759, GO:0005753, GO:0000275, GO:0005739, GO:0046933, GO:0003723, GO:0006754, GO:0006119, GO:0015986, GO:0042776, IPR035968, IPR000131, IPR023632, P36542",3,8H9I,wlidetype,P36542,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,7
8H9L,,,,,,8H9L,Structure of the human ATP synthase.,"Human ATP synthase F1 domain, state 3a",MEMBRANE PROTEIN,"ATP5F1C, ATP5C, ATP5C1, ATP5CL1",,"GO:0016020, GO:0005743, GO:0005759, GO:0005753, GO:0000275, GO:0005739, GO:0046933, GO:0003723, GO:0006754, GO:0006119, GO:0015986, GO:0042776, IPR035968, IPR000131, IPR023632, P36542",3,8H9L,wlidetype,P36542,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,6
8H9L,,,,,,8H9L,Structure of the human ATP synthase.,"Human ATP synthase F1 domain, state 3a",MEMBRANE PROTEIN,"ATP5F1A, ATP5A, ATP5A1, ATP5AL2, ATPM",,"GO:0009986, GO:0070062, GO:0016020, GO:0045121, GO:0005743, GO:0005759, GO:0005753, GO:0005754, GO:0005739, GO:0005634, GO:0005886, GO:0045259, GO:0045261, GO:0043531, GO:0043532, GO:0005524, GO:0016887, GO:0042288, GO:0002020, GO:0046933, GO:0003723, GO:0006915, GO:0006754, GO:0071549, GO:0071732, GO:0006629, GO:0001937, GO:0043536, GO:0015986, GO:0042776, GO:0045471, GO:0014850, IPR023366, IPR000793, IPR038376, IPR033732, IPR005294, IPR020003, IPR004100, IPR036121, IPR000194, IPR027417, P25705",1,8H9L,wlidetype,P25705,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,8
8H9P,,,,,,8H9P,Structure of the human ATP synthase.,"Human ATP synthase F1 domain, state 3b",MEMBRANE PROTEIN,"ATP5F1A, ATP5A, ATP5A1, ATP5AL2, ATPM",,"GO:0009986, GO:0070062, GO:0016020, GO:0045121, GO:0005743, GO:0005759, GO:0005753, GO:0005754, GO:0005739, GO:0005634, GO:0005886, GO:0045259, GO:0045261, GO:0043531, GO:0043532, GO:0005524, GO:0016887, GO:0042288, GO:0002020, GO:0046933, GO:0003723, GO:0006915, GO:0006754, GO:0071549, GO:0071732, GO:0006629, GO:0001937, GO:0043536, GO:0015986, GO:0042776, GO:0045471, GO:0014850, IPR023366, IPR000793, IPR038376, IPR033732, IPR005294, IPR020003, IPR004100, IPR036121, IPR000194, IPR027417, P25705",1,8H9P,wlidetype,P25705,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,5
8H9P,,,,,,8H9P,Structure of the human ATP synthase.,"Human ATP synthase F1 domain, state 3b",MEMBRANE PROTEIN,"ATP5F1C, ATP5C, ATP5C1, ATP5CL1",,"GO:0016020, GO:0005743, GO:0005759, GO:0005753, GO:0000275, GO:0005739, GO:0046933, GO:0003723, GO:0006754, GO:0006119, GO:0015986, GO:0042776, IPR035968, IPR000131, IPR023632, P36542",3,8H9P,wlidetype,P36542,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,7
8H9S,,,,,,8H9S,Structure of the human ATP synthase.,Human ATP synthase state 1 (combined),MEMBRANE PROTEIN,"ATP5PF, ATP5A, ATP5J, ATPM",,"GO:0005743, GO:0005753, GO:0000276, GO:0005739, GO:0015078, GO:0015986, GO:0042776, GO:0021762, IPR008387, IPR036204, P18859, Transmembrane.Alpha-helical polytopic.Proton or Sodium translocating F-type, V-type and A-type ATPases.V-type and F-type ATPases",2,8H9S,wlidetype,P18859,UniProt,C81 H156 O17 P2,1464.043,CDL,CARDIOLIPIN,CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCC(COP(=O)([O-])OCC(COC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC)O)OC(=O)CCCCCCCCCCCCCCCCC,18
8H9S,,,,,,8H9S,Structure of the human ATP synthase.,Human ATP synthase state 1 (combined),MEMBRANE PROTEIN,"ATP5MC1, ATP5G1",,"GO:0005743, GO:0005753, GO:0000276, GO:0005739, GO:0008289, GO:0015078, GO:0015986, IPR000454, IPR020537, IPR038662, IPR002379, IPR035921, P05496, Transmembrane.Alpha-helical polytopic.Proton or Sodium translocating F-type, V-type and A-type ATPases.V-type and F-type ATPases",9,8H9S,wlidetype,P05496,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,21
8H9S,,,,,,8H9S,Structure of the human ATP synthase.,Human ATP synthase state 1 (combined),MEMBRANE PROTEIN,"ATP5PB, ATP5F1",,"GO:0016020, GO:0005743, GO:0005759, GO:0005753, GO:0000276, GO:0005739, GO:0005634, GO:0015078, GO:0015986, GO:0042776, GO:0021762, IPR008688, IPR013837, P24539, Transmembrane.Alpha-helical polytopic.Proton or Sodium translocating F-type, V-type and A-type ATPases.V-type and F-type ATPases",1,8H9S,wlidetype,P24539,UniProt,C39 H77 O8 P,704.998,3PH,"1,2-DIACYL-GLYCEROL-3-SN-PHOSPHATE",CCCCCCCCCCCCCCCCCC(=O)OCC(COP(=O)(O)O)OC(=O)CCCCCCCCCCCCCCCCC,22
8H9S,,,,,,8H9S,Structure of the human ATP synthase.,Human ATP synthase state 1 (combined),MEMBRANE PROTEIN,"ATP5F1D, ATP5D",,"GO:0005743, GO:0005759, GO:0005753, GO:0000275, GO:0005739, GO:0046933, GO:0009060, GO:0033615, GO:0015986, GO:0042776, GO:0046688, IPR036794, IPR001469, IPR020546, IPR036771, P30049, Transmembrane.Alpha-helical polytopic.Proton or Sodium translocating F-type, V-type and A-type ATPases.V-type and F-type ATPases",10,8H9S,wlidetype,P30049,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,19
8H9T,,,,,,8H9T,Structure of the human ATP synthase.,Human ATP synthase state 2 (combined),MEMBRANE PROTEIN,"ATP5PD, ATP5H, My032",,"GO:0005743, GO:0005753, GO:0000274, GO:0005739, GO:0015078, GO:0015986, GO:0042776, IPR008689, IPR036228, O75947, Transmembrane.Alpha-helical polytopic.Proton or Sodium translocating F-type, V-type and A-type ATPases.V-type and F-type ATPases",3,8H9T,wlidetype,O75947,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,17
8H9T,,,,,,8H9T,Structure of the human ATP synthase.,Human ATP synthase state 2 (combined),MEMBRANE PROTEIN,"ATP5F1C, ATP5C, ATP5C1, ATP5CL1",,"GO:0016020, GO:0005743, GO:0005759, GO:0005753, GO:0000275, GO:0005739, GO:0046933, GO:0003723, GO:0006754, GO:0006119, GO:0015986, GO:0042776, IPR035968, IPR000131, IPR023632, P36542, Transmembrane.Alpha-helical polytopic.Proton or Sodium translocating F-type, V-type and A-type ATPases.V-type and F-type ATPases",15,8H9T,wlidetype,P36542,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,19
8H9U,,,,,,8H9U,Structure of the human ATP synthase.,Human ATP synthase state 3a (combined),MEMBRANE PROTEIN,"ATP5F1A, ATP5A, ATP5A1, ATP5AL2, ATPM",,"GO:0009986, GO:0070062, GO:0016020, GO:0045121, GO:0005743, GO:0005759, GO:0005753, GO:0005754, GO:0005739, GO:0005634, GO:0005886, GO:0045259, GO:0045261, GO:0043531, GO:0043532, GO:0005524, GO:0016887, GO:0042288, GO:0002020, GO:0046933, GO:0003723, GO:0006915, GO:0006754, GO:0071549, GO:0071732, GO:0006629, GO:0001937, GO:0043536, GO:0015986, GO:0042776, GO:0045471, GO:0014850, IPR023366, IPR000793, IPR038376, IPR033732, IPR005294, IPR020003, IPR004100, IPR036121, IPR000194, IPR027417, P25705, Transmembrane.Alpha-helical polytopic.Proton or Sodium translocating F-type, V-type and A-type ATPases.V-type and F-type ATPases",1,8H9U,wlidetype,P25705,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,18
8H9U,,,,,,8H9U,Structure of the human ATP synthase.,Human ATP synthase state 3a (combined),MEMBRANE PROTEIN,"MT-ATP6, ATP6, ATPASE6, MTATP6",,"GO:0005743, GO:0005753, GO:0045263, GO:0015078, GO:0015986, GO:0042776, GO:0055093, IPR000568, IPR023011, IPR045083, IPR035908, P00846, Transmembrane.Alpha-helical polytopic.Proton or Sodium translocating F-type, V-type and A-type ATPases.V-type and F-type ATPases",11,8H9U,wlidetype,P00846,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,20
8H9V,,,,,,8H9V,Structure of the human ATP synthase.,Human ATP synthase state 3b (combined),MEMBRANE PROTEIN,"ATP5F1D, ATP5D",,"GO:0005743, GO:0005759, GO:0005753, GO:0000275, GO:0005739, GO:0046933, GO:0009060, GO:0033615, GO:0015986, GO:0042776, GO:0046688, IPR036794, IPR001469, IPR020546, IPR036771, P30049, Transmembrane.Alpha-helical polytopic.Proton or Sodium translocating F-type, V-type and A-type ATPases.V-type and F-type ATPases, Generic PDBTM",2,8H9V,wlidetype,P30049,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,17
8H9V,,,,,,8H9V,Structure of the human ATP synthase.,Human ATP synthase state 3b (combined),MEMBRANE PROTEIN,"ATP5MJ, ATP5MPL, C14orf2, MP68, PRO1574",,"GO:0005743, GO:0005753, GO:0015986, IPR012574, P56378, Transmembrane.Alpha-helical polytopic.Proton or Sodium translocating F-type, V-type and A-type ATPases.V-type and F-type ATPases, Generic PDBTM",7,8H9V,wlidetype,P56378,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,19
8HJ5,,,,,,8HJ5,Cryo-EM structure of Gq-coupled MRGPRX1 bound with  Compound-16,Cryo-EM structure of Gq-coupled MRGPRX1 bound with Compound-16,SIGNALING PROTEIN,,,,6,8HJ5,mutant,,,C23 H21 N3 O4 S,435.496,U2U,N-{2-[(1-aminoisoquinolin-6-yl)oxy]-4-methylphenyl}-2-methoxybenzene-1-sulfonamide,Cc1ccc(c(c1)Oc2ccc3c(c2)ccnc3N)NS(=O)(=O)c4ccccc4OC,7
8HJE,,,,,,8HJE,Structure-based discovery of potent USP28 inhibitors derived from Vismodegib.,Vismodegib binds to the catalytical domain of human Ubiquitin-Specific Protease 28,HYDROLASE,"USP28, KIAA1515",3.4.19.12,"GO:0005829, GO:0016604, GO:0005654, GO:0005634, GO:0032991, GO:0004843, GO:0004197, GO:0008283, GO:0006974, GO:0034644, GO:0000077, GO:0006281, GO:0042771, GO:0016579, GO:0007265, GO:0031647, GO:0010212, GO:0006511, IPR038765, IPR001394, IPR009060, IPR018200, IPR028889, Q96RU2",1,8HJE,wlidetype,Q96RU2,UniProt,C19 H14 Cl2 N2 O3 S,421.297,VIS,2-chloranyl-~{N}-(4-chloranyl-3-pyridin-2-yl-phenyl)-4-methylsulfonyl-benzamide,CS(=O)(=O)c1ccc(c(c1)Cl)C(=O)Nc2ccc(c(c2)c3ccccn3)Cl,2
8HN7,,,,,,8HN7,Characterization of RBD-specific cross-neutralizing antibodies responses against SARS-CoV-2 variants from COVID-19 convalescents.,Crystal structure of monoclonal antibody complexed with SARS-CoV-2 RBD,VIRAL PROTEIN/IMMUNE SYSTEM,,,,1,8HN7,wlidetype,,,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,4
8I4A,,,,,,8I4A,Cryo-EM structure ofABCC4,Cryo-EM structure of dipyridamole-bound ABCC4,TRANSPORT PROTEIN,"ABCC4, MOATB, MRP4","7.6.2, 7.6.2.2, 7.6.2.3","GO:0016324, GO:0016323, GO:0098591, GO:0005794, GO:0016020, GO:0005730, GO:0005886, GO:0031088, GO:0016404, GO:0015432, GO:0015431, GO:0140359, GO:0008559, GO:0005524, GO:0016887, GO:0043225, GO:0042626, GO:0015562, GO:0034634, GO:0001409, GO:0015132, GO:0015216, GO:0015143, GO:0042910, GO:0015721, GO:0070730, GO:0060271, GO:0140115, GO:0071716, GO:0002576, GO:0032310, GO:0015732, GO:0055085, GO:0150104, GO:0015747, GO:0006805, GO:0006855, IPR003593, IPR011527, IPR036640, IPR003439, IPR017871, IPR030240, IPR047083, IPR027417, O15439, Transmembrane.Alpha-helical polytopic.ABC transporters.Drug conjugate transporter (ABC C family), Generic PDBTM",1,8I4A,wlidetype,O15439,UniProt,C24 H40 N8 O4,504.626,H9F,"2-[[2-[bis(2-hydroxyethyl)amino]-4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidin-6-yl]-(2-hydroxyethyl)amino]ethanol",C1CCN(CC1)c2c3c(c(nc(n3)N(CCO)CCO)N4CCCCC4)nc(n2)N(CCO)CCO,2
8I4C,,,,,,8I4C,Cryo-EM structure ofABCC4,Cryo-EM structure of U46619-bound ABCC4,TRANSPORT PROTEIN,"ABCC4, MOATB, MRP4","7.6.2, 7.6.2.2, 7.6.2.3","GO:0016324, GO:0016323, GO:0098591, GO:0005794, GO:0016020, GO:0005730, GO:0005886, GO:0031088, GO:0016404, GO:0015432, GO:0015431, GO:0140359, GO:0008559, GO:0005524, GO:0016887, GO:0043225, GO:0042626, GO:0015562, GO:0034634, GO:0001409, GO:0015132, GO:0015216, GO:0015143, GO:0042910, GO:0015721, GO:0070730, GO:0060271, GO:0140115, GO:0071716, GO:0002576, GO:0032310, GO:0015732, GO:0055085, GO:0150104, GO:0015747, GO:0006805, GO:0006855, IPR003593, IPR011527, IPR036640, IPR003439, IPR017871, IPR030240, IPR047083, IPR027417, O15439, Transmembrane.Alpha-helical polytopic.ABC transporters.Drug conjugate transporter (ABC C family), Generic PDBTM",1,8I4C,wlidetype,O15439,UniProt,C21 H34 O4,350.492,PUC,"(5Z)-7-{(1R,4S,5S,6R)-6-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-2-oxabicyclo[2.2.1]hept-5-yl}hept-5-enoic acid",CCCCCC(C=CC1C2CC(C1CC=CCCCC(=O)O)CO2)O,2
8IF2,,,,,,8IF2,Convergent evolution of SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant.,Crystal structure of the receptor binding domain of SARS-CoV-2 Omicron BQ.1.1 variant spike protein in complex with its receptor ACE2,VIRAL PROTEIN,"S, 2",,"GO:0044173, GO:0020002, GO:0016020, GO:0019031, GO:0055036, GO:0046789, GO:0042802, GO:0075509, GO:0039654, GO:0019064, GO:0061025, GO:0046598, GO:0019065, GO:0046813, GO:0039587, GO:0039502, GO:0046718, GO:0019058, IPR032500, IPR042578, IPR043607, IPR043473, IPR043002, IPR044341, IPR018548, IPR044366, IPR036326, IPR002552, IPR044873, IPR044874, P0DTC2",2,8IF2,mutant,P0DTC2,UniProt,C8 H15 N O6,221.208,NAG,2-acetamido-2-deoxy-beta-D-glucopyranose,CC(=O)NC1C(C(C(OC1O)CO)O)O,7
8ITF,,,,,,8ITF,Structural basis of amine odorant perception by a mammal olfactory receptor.,Cryo-EM structure of the DMCHA-bound mTAAR9-Gs complex,MEMBRANE PROTEIN,GNB1,,"GO:0005737, GO:0005829, GO:0070062, GO:1903561, GO:0005834, GO:0005765, GO:0016020, GO:0097381, GO:0005886, GO:0045202, GO:0003924, GO:0051020, GO:0044877, GO:0030159, GO:0007191, GO:0008283, GO:0071870, GO:0071380, GO:0007213, GO:0007186, GO:0007200, GO:0007265, GO:0060041, GO:0050909, GO:0007165, IPR020472, IPR001632, IPR016346, IPR015943, IPR001680, IPR019775, IPR036322, P62873",2,8ITF,wlidetype,P62873,UniProt,C8 H17 N,127.227,8IA,"~{N},~{N}-dimethylcyclohexanamine",CN(C)C1CCCCC1,7
8IW4,,,,,,8IW4,Structural basis of amine odorant perception by a mammal olfactory receptor.,Cryo-EM structure of the SPE-bound mTAAR9-Gs complex,MEMBRANE PROTEIN,,,,1,8IW4,wlidetype,,,C7 H19 N3,145.246,SPD,SPERMIDINE,C(CCNCCCN)CN,6
8IW7,,,,,,8IW7,Structural basis of amine odorant perception by a mammal olfactory receptor.,Cryo-EM structure of the PEA-bound mTAAR9-Gs complex,MEMBRANE PROTEIN,Taar9,,"GO:0005886, GO:0001594, IPR000276, IPR017452, IPR009132, Q5QD04, Transmembrane.Alpha-helical polytopic.Rhodopsin-like receptors and pumps.G-protein coupled receptors, family A, Generic PDBTM",1,8IW7,wlidetype,Q5QD04,UniProt,C8 H12 N,122.188,PEA,2-PHENYLETHYLAMINE,c1ccc(cc1)CC[NH3+],6
8J3W,,,,,,8J3W,Cryo-EM structure ofABCC4,Cryo-EM structure of aspirin-bound ABCC4,TRANSPORT PROTEIN,"ABCC4, MOATB, MRP4","7.6.2, 7.6.2.2, 7.6.2.3","GO:0016324, GO:0016323, GO:0098591, GO:0005794, GO:0016020, GO:0005730, GO:0005886, GO:0031088, GO:0016404, GO:0015432, GO:0015431, GO:0140359, GO:0008559, GO:0005524, GO:0016887, GO:0043225, GO:0042626, GO:0015562, GO:0034634, GO:0001409, GO:0015132, GO:0015216, GO:0015143, GO:0042910, GO:0015721, GO:0070730, GO:0060271, GO:0140115, GO:0071716, GO:0002576, GO:0032310, GO:0015732, GO:0055085, GO:0150104, GO:0015747, GO:0006805, GO:0006855, IPR003593, IPR011527, IPR036640, IPR003439, IPR017871, IPR030240, IPR047083, IPR027417, O15439, Transmembrane.Alpha-helical polytopic.ABC transporters.Drug conjugate transporter (ABC C family), Generic PDBTM",1,8J3W,wlidetype,O15439,UniProt,C9 H8 O4,180.157,AIN,2-(ACETYLOXY)BENZOIC ACID,CC(=O)Oc1ccccc1C(=O)O,2
8J3Z,,,,,,8J3Z,Cryo-EM structure ofABCC4,Cryo-EM structure of ATP-U46619-bound ABCC4,TRANSPORT PROTEIN,"ABCC4, MOATB, MRP4","7.6.2, 7.6.2.2, 7.6.2.3","GO:0016324, GO:0016323, GO:0098591, GO:0005794, GO:0016020, GO:0005730, GO:0005886, GO:0031088, GO:0016404, GO:0015432, GO:0015431, GO:0140359, GO:0008559, GO:0005524, GO:0016887, GO:0043225, GO:0042626, GO:0015562, GO:0034634, GO:0001409, GO:0015132, GO:0015216, GO:0015143, GO:0042910, GO:0015721, GO:0070730, GO:0060271, GO:0140115, GO:0071716, GO:0002576, GO:0032310, GO:0015732, GO:0055085, GO:0150104, GO:0015747, GO:0006805, GO:0006855, IPR003593, IPR011527, IPR036640, IPR003439, IPR017871, IPR030240, IPR047083, IPR027417, O15439, Transmembrane.Alpha-helical polytopic.ABC transporters.Drug conjugate transporter (ABC C family), Generic PDBTM",1,8J3Z,wlidetype,O15439,UniProt,C21 H34 O4,350.492,PUC,"(5Z)-7-{(1R,4S,5S,6R)-6-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-2-oxabicyclo[2.2.1]hept-5-yl}hept-5-enoic acid",CCCCCC(C=CC1C2CC(C1CC=CCCCC(=O)O)CO2)O,4
8OLX,,,,,,8OLX,MutSbeta bound to (CAG)2 DNA (canonical form),MutSbeta bound to (CAG)2 DNA (canonical form),DNA BINDING PROTEIN,"MSH3, DUC1, DUG",,"GO:0016020, GO:0032302, GO:0005654, GO:0005634, GO:0005524, GO:0140664, GO:0003690, GO:0019899, GO:0030983, GO:0006281, GO:0043570, GO:0006298, GO:0006312, GO:0045910, GO:0051096, GO:0016447, IPR007695, IPR000432, IPR007696, IPR016151, IPR036187, IPR007860, IPR036678, IPR045076, IPR027417, P20585",2,8OLX,mutant,P20585,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,6
8OM5,,,,,,8OM5,DNA-free open form of MutSbeta,DNA-free open form of MutSbeta,DNA BINDING PROTEIN,MSH2,,"GO:0000781, GO:0016020, GO:0032301, GO:0032302, GO:0005654, GO:0005634, GO:0005524, GO:0016887, GO:0008094, GO:0140664, GO:0019237, GO:0003682, GO:0003684, GO:0003677, GO:0019899, GO:0032137, GO:0042803, GO:0019901, GO:0030183, GO:0019724, GO:0008340, GO:0006281, GO:0006302, GO:0007281, GO:0001701, GO:0042771, GO:0045190, GO:0043570, GO:0008584, GO:0006298, GO:0031573, GO:0006312, GO:0045910, GO:0043524, GO:0006119, GO:0051096, GO:0048298, GO:0048304, GO:0006301, GO:0071168, GO:0010224, GO:0010165, GO:0016446, GO:0016447, GO:0002204, IPR011184, IPR007695, IPR000432, IPR007861, IPR007696, IPR016151, IPR036187, IPR007860, IPR032642, IPR036678, IPR045076, IPR027417, P43246",1,8OM5,mutant,P43246,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,3
8OM9,,,,,,8OM9,MutSbeta bound to (CAG)2 DNA (open form),MutSbeta bound to (CAG)2 DNA (open form),DNA BINDING PROTEIN,MSH2,,"GO:0000781, GO:0016020, GO:0032301, GO:0032302, GO:0005654, GO:0005634, GO:0005524, GO:0016887, GO:0008094, GO:0140664, GO:0019237, GO:0003682, GO:0003684, GO:0003677, GO:0019899, GO:0032137, GO:0042803, GO:0019901, GO:0030183, GO:0019724, GO:0008340, GO:0006281, GO:0006302, GO:0007281, GO:0001701, GO:0042771, GO:0045190, GO:0043570, GO:0008584, GO:0006298, GO:0031573, GO:0006312, GO:0045910, GO:0043524, GO:0006119, GO:0051096, GO:0048298, GO:0048304, GO:0006301, GO:0071168, GO:0010224, GO:0010165, GO:0016446, GO:0016447, GO:0002204, IPR011184, IPR007695, IPR000432, IPR007861, IPR007696, IPR016151, IPR036187, IPR007860, IPR032642, IPR036678, IPR045076, IPR027417, P43246",1,8OM9,mutant,P43246,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,5
8OMA,,,,,,8OMA,MutSbeta bound to 61bp homoduplex DNA,MutSbeta bound to 61bp homoduplex DNA,DNA BINDING PROTEIN,,,,1,8OMA,mutant,,,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,5
8OMO,,,,,,8OMO,DNA-unbound MutSbeta-ATP complex (bent clamp form),DNA-unbound MutSbeta-ATP complex (bent clamp form),DNA BINDING PROTEIN,MSH2,,"GO:0000781, GO:0016020, GO:0032301, GO:0032302, GO:0005654, GO:0005634, GO:0005524, GO:0016887, GO:0008094, GO:0140664, GO:0019237, GO:0003682, GO:0003684, GO:0003677, GO:0019899, GO:0032137, GO:0042803, GO:0019901, GO:0030183, GO:0019724, GO:0008340, GO:0006281, GO:0006302, GO:0007281, GO:0001701, GO:0042771, GO:0045190, GO:0043570, GO:0008584, GO:0006298, GO:0031573, GO:0006312, GO:0045910, GO:0043524, GO:0006119, GO:0051096, GO:0048298, GO:0048304, GO:0006301, GO:0071168, GO:0010224, GO:0010165, GO:0016446, GO:0016447, GO:0002204, IPR011184, IPR007695, IPR000432, IPR007861, IPR007696, IPR016151, IPR036187, IPR007860, IPR032642, IPR036678, IPR045076, IPR027417, P43246",1,8OMO,mutant,P43246,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,3
8OMQ,,,,,,8OMQ,DNA-unbound MutSbeta-ATP complex (straight clamp form),DNA-unbound MutSbeta-ATP complex (straight clamp form),DNA BINDING PROTEIN,"MSH3, DUC1, DUG",,"GO:0016020, GO:0032302, GO:0005654, GO:0005634, GO:0005524, GO:0140664, GO:0003690, GO:0019899, GO:0030983, GO:0006281, GO:0043570, GO:0006298, GO:0006312, GO:0045910, GO:0051096, GO:0016447, IPR007695, IPR000432, IPR007696, IPR016151, IPR036187, IPR007860, IPR036678, IPR045076, IPR027417, P20585",1,8OMQ,mutant,P20585,UniProt,C10 H16 N5 O13 P3,507.181,ATP,ADENOSINE-5'-TRIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O)N,3
8OO5,,,,,,8OO5,Reinstating targeted protein degradation with DCAF1 PROTACs in CRBN PROTAC resistant settings,Crystal structure of human DCAF1 WD40 repeats (Q1250L) in complex with compound 13,TRANSFERASE,"DCAF1, KIAA0800, RIP, VPRBP",2.7.11.1,"GO:0080008, GO:0005737, GO:0001650, GO:0005654, GO:0005634, GO:0005524, GO:1990244, GO:0030331, GO:0106310, GO:0030183, GO:0035212, GO:0006325, GO:0000122, GO:0043687, GO:0016567, GO:0033151, IPR011989, IPR016024, IPR006594, IPR033270, IPR015943, IPR036322, Q9Y4B6",1,8OO5,mutant,Q9Y4B6,UniProt,C28 H35 Cl N6 O,507.07,VUF,1-[4-[4-(2-azanylethylamino)-2-[1-(4-chlorophenyl)cyclohexyl]quinazolin-7-yl]piperazin-1-yl]ethanone,CC(=O)N1CCN(CC1)c2ccc3c(c2)nc(nc3NCCN)C4(CCCCC4)c5ccc(cc5)Cl,2
8OOD,,,,,,8OOD,Reinstating targeted protein degradation with DCAF1 PROTACs in CRBN PROTAC resistant settings,Crystal structure of human DCAF1 WD40 repeats (Q1250L) in complex with compound 15,TRANSFERASE,"DCAF1, KIAA0800, RIP, VPRBP",2.7.11.1,"GO:0080008, GO:0005737, GO:0001650, GO:0005654, GO:0005634, GO:0005524, GO:1990244, GO:0030331, GO:0106310, GO:0030183, GO:0035212, GO:0006325, GO:0000122, GO:0043687, GO:0016567, GO:0033151, IPR011989, IPR016024, IPR006594, IPR033270, IPR015943, IPR036322, Q9Y4B6",1,8OOD,mutant,Q9Y4B6,UniProt,C42 H62 Cl N7 O8,828.437,VY3,~{N}-[2-[2-[2-[2-[2-[2-[3-[4-[4-(2-azanylethylamino)-2-[1-(4-chlorophenyl)cyclopentyl]quinazolin-7-yl]piperazin-1-yl]-3-oxidanylidene-propoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl]ethanamide,CC(=O)NCCOCCOCCOCCOCCOCCOCCC(=O)N1CCN(CC1)c2ccc3c(c2)nc(nc3NCCN)C4(CCCC4)c5ccc(cc5)Cl,5
8P0F,,,,,,8P0F,Drugit: Crowd-sourcing molecular design of non-peptidic VHL binders,Crystal structure of the VCB complex with compound 1.,LIGASE,VHL,,"GO:0005829, GO:0005783, GO:0016020, GO:0005739, GO:0005654, GO:0005634, GO:0140297, GO:0019899, GO:0003711, GO:1990756, GO:0004842, GO:0000902, GO:0043066, GO:0008285, GO:0010629, GO:0046426, GO:0034244, GO:0061428, GO:0045597, GO:0045893, GO:0050821, GO:0016567, GO:0006508, GO:0061418, GO:0006355, IPR002714, IPR024048, IPR037139, IPR024053, IPR037140, IPR036208, IPR022772, P40337",1,8P0F,wlidetype,P40337,UniProt,C22 H22 N4 O3 S,422.5,WBN,"(3~{R},5~{R})-~{N}-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]-5-oxidanyl-2-oxidanylidene-1-pyridin-2-yl-piperidine-3-carboxamide",Cc1c(scn1)c2ccc(cc2)CNC(=O)C3CC(CN(C3=O)c4ccccn4)O,4
8SEO,,,,,,8SEO,Allosteric modulation of ryanodine receptor RyR1 by nucleotide derivatives.,Cryo-EM Structure of RyR1 + ATP-gamma-S,TRANSPORT PROTEIN,RYR1,,"GO:0016020, GO:1990425, GO:0016529, GO:0033017, GO:0014802, GO:0005524, GO:0035381, GO:0005262, GO:0005509, GO:0015278, GO:0005516, GO:0097718, GO:0042802, GO:0005219, GO:0015643, GO:0044325, GO:0005245, GO:0070588, GO:0006874, GO:0071313, GO:0071277, GO:0006936, GO:0043931, GO:0003151, GO:0051289, GO:0051209, GO:0014808, GO:0048741, GO:0043588, IPR001870, IPR043136, IPR013320, IPR011992, IPR014821, IPR005821, IPR036300, IPR016093, IPR013662, IPR000699, IPR013333, IPR003032, IPR009460, IPR035910, IPR033215, IPR035761, IPR035764, IPR035762, IPR003877, Transmembrane.Alpha-helical polytopic.Ion channel (VIC) superfamily.Ryanodine receptor",1,8SEO,wlidetype,P11716,UniProt,C10 H16 N5 O12 P3 S,523.247,AGS,PHOSPHOTHIOPHOSPHORIC ACID-ADENYLATE ESTER,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)OP(=S)(O)O)O)O)N,3
45177,,,,,,45177,Allosteric modulation of ryanodine receptor RyR1 by nucleotide derivatives.,Cryo-EM Structure of RyR1 + ADP,TRANSPORT PROTEIN,FKBP1B,"2.5.1.18, 5.2.1.8","GO:0004364, GO:0006749, IPR010987, IPR036282, IPR040079, IPR004045, IPR004046, IPR036249, GO:0034704, GO:0005737, GO:0005829, GO:0016020, GO:0033017, GO:0030018, GO:0019855, GO:0030551, GO:0005528, GO:0003755, GO:0005102, GO:0044325, GO:0006458, GO:0035584, GO:0086064, GO:0061077, GO:0035773, GO:0010459, GO:0061179, GO:0032515, GO:0051280, GO:0060315, GO:0019227, GO:0048680, GO:0007204, GO:0051284, GO:0022417, GO:0000413, GO:0042026, GO:0010881, GO:0051480, GO:0010880, GO:0060314, GO:0051209, GO:0042542, GO:0051775, GO:0033197, GO:0006939, GO:0042098, IPR046357, IPR001179, P68106",2,08-Sep,,P08515,UniProt,C10 H15 N5 O10 P2,427.201,ADP,ADENOSINE-5'-DIPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)OP(=O)(O)O)O)O)N,3
8SEQ,,,,,,8SEQ,Allosteric modulation of ryanodine receptor RyR1 by nucleotide derivatives.,Cryo-EM Structure of RyR1 + AMP,TRANSPORT PROTEIN,RYR1,,"GO:0016020, GO:1990425, GO:0016529, GO:0033017, GO:0014802, GO:0005524, GO:0035381, GO:0005262, GO:0005509, GO:0015278, GO:0005516, GO:0097718, GO:0042802, GO:0005219, GO:0015643, GO:0044325, GO:0005245, GO:0070588, GO:0006874, GO:0071313, GO:0071277, GO:0006936, GO:0043931, GO:0003151, GO:0051289, GO:0051209, GO:0014808, GO:0048741, GO:0043588, IPR001870, IPR043136, IPR013320, IPR011992, IPR014821, IPR005821, IPR036300, IPR016093, IPR013662, IPR000699, IPR013333, IPR003032, IPR009460, IPR035910, IPR033215, IPR035761, IPR035764, IPR035762, IPR003877, Transmembrane.Alpha-helical polytopic.Ion channel (VIC) superfamily.Ryanodine receptor",1,8SEQ,wlidetype,P11716,UniProt,C10 H14 N5 O7 P,347.221,AMP,ADENOSINE MONOPHOSPHATE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)COP(=O)(O)O)O)O)N,3
8SER,,,,,,8SER,Allosteric modulation of ryanodine receptor RyR1 by nucleotide derivatives.,Cryo-EM Structure of RyR1 + Adenosine,TRANSPORT PROTEIN,RYR1,,"GO:0016020, GO:1990425, GO:0016529, GO:0033017, GO:0014802, GO:0005524, GO:0035381, GO:0005262, GO:0005509, GO:0015278, GO:0005516, GO:0097718, GO:0042802, GO:0005219, GO:0015643, GO:0044325, GO:0005245, GO:0070588, GO:0006874, GO:0071313, GO:0071277, GO:0006936, GO:0043931, GO:0003151, GO:0051289, GO:0051209, GO:0014808, GO:0048741, GO:0043588, IPR001870, IPR043136, IPR013320, IPR011992, IPR014821, IPR005821, IPR036300, IPR016093, IPR013662, IPR000699, IPR013333, IPR003032, IPR009460, IPR035910, IPR033215, IPR035761, IPR035764, IPR035762, IPR003877, Transmembrane.Alpha-helical polytopic.Ion channel (VIC) superfamily.Ryanodine receptor",1,8SER,wlidetype,P11716,UniProt,C10 H13 N5 O4,267.241,ADN,ADENOSINE,c1nc(c2c(n1)n(cn2)C3C(C(C(O3)CO)O)O)N,3
8SES,,,,,,8SES,Allosteric modulation of ryanodine receptor RyR1 by nucleotide derivatives.,Cryo-EM Structure of RyR1 + Adenine,TRANSPORT PROTEIN,FKBP1B,"2.5.1.18, 5.2.1.8","GO:0004364, GO:0006749, IPR010987, IPR036282, IPR040079, IPR004045, IPR004046, IPR036249, GO:0034704, GO:0005737, GO:0005829, GO:0016020, GO:0033017, GO:0030018, GO:0019855, GO:0030551, GO:0005528, GO:0003755, GO:0005102, GO:0044325, GO:0006458, GO:0035584, GO:0086064, GO:0061077, GO:0035773, GO:0010459, GO:0061179, GO:0032515, GO:0051280, GO:0060315, GO:0019227, GO:0048680, GO:0007204, GO:0051284, GO:0022417, GO:0000413, GO:0042026, GO:0010881, GO:0051480, GO:0010880, GO:0060314, GO:0051209, GO:0042542, GO:0051775, GO:0033197, GO:0006939, GO:0042098, IPR046357, IPR001179, P68106",2,8SES,wlidetype,P08515,UniProt,C5 H5 N5,135.127,ADE,ADENINE,c1[nH]c2c(n1)c(ncn2)N,4
8SET,,,,,,8SET,Allosteric modulation of ryanodine receptor RyR1 by nucleotide derivatives.,Cryo-EM Structure of RyR1 + cAMP,TRANSPORT PROTEIN,RYR1,,"GO:0016020, GO:1990425, GO:0016529, GO:0033017, GO:0014802, GO:0005524, GO:0035381, GO:0005262, GO:0005509, GO:0015278, GO:0005516, GO:0097718, GO:0042802, GO:0005219, GO:0015643, GO:0044325, GO:0005245, GO:0070588, GO:0006874, GO:0071313, GO:0071277, GO:0006936, GO:0043931, GO:0003151, GO:0051289, GO:0051209, GO:0014808, GO:0048741, GO:0043588, IPR001870, IPR043136, IPR013320, IPR011992, IPR014821, IPR005821, IPR036300, IPR016093, IPR013662, IPR000699, IPR013333, IPR003032, IPR009460, IPR035910, IPR033215, IPR035761, IPR035764, IPR035762, IPR003877, Transmembrane.Alpha-helical polytopic.Ion channel (VIC) superfamily.Ryanodine receptor",1,8SET,wlidetype,P11716,UniProt,C10 H12 N5 O6 P,329.206,CMP,"ADENOSINE-3',5'-CYCLIC-MONOPHOSPHATE",c1nc(c2c(n1)n(cn2)C3C(C4C(O3)COP(=O)(O4)O)O)N,3
8STE,,,,,,8STE,Inhibition mechanism of NKCC1 involves the carboxyl terminus and long-range conformational coupling.,Cryo-EM structure of NKCC1 Fu_CTD,TRANSPORT PROTEIN,SLC12A2,,"GO:0005886, GO:0015377, GO:0006814, IPR004841, IPR013612, IPR002444, IPR018491, IPR002443, IPR004842",1,8STE,wlidetype,A0A8C9GPS0,UniProt,C12 H11 Cl N2 O5 S,330.744,FUN,5-(AMINOSULFONYL)-4-CHLORO-2-[(2-FURYLMETHYL)AMINO]BENZOIC ACID,c1cc(oc1)CNc2cc(c(cc2C(=O)O)S(=O)(=O)N)Cl,2
